# 2025年11月4日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. NapRNAdb：一个用于napRNA发现和功能注释的多物种知识库与分析平台。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41182820](https://pubmed.ncbi.nlm.nih.gov/41182820)
**期刊：** Nucleic acids research
**PMID：** 41182820
**DOI：** 10.1093/nar/gkaf1100

### 第一部分 原文与翻译

**英文原标题：** NapRNAdb: a multispecies repository and analytical platform for napRNA discovery and functional annotation.

**英文摘要原文：**
Over 75% of the human genome transcribes noncapped RNAs (napRNAs), which typically function as noncoding RNAs in gene expression regulation. While short napRNAs (e.g. small RNAs) have well-defined transcriptomic roles, long napRNAs with diverse terminal modifications remain poorly characterized. To advance research, we developed NapRNAdb (https://bioinformaticsscience.cn/naprnadb), the first database dedicated to NAP-seq-derived napRNAs, enabling cross-species napRNA transcriptome profiling (40 species). This resource integrates 30 708 napRNAs derived from human and mouse NAP-seq with their expression profiles in multiple biological models, comprising 1016 ACA-napRNAs, 297 CD-napRNAs, 2302 Pol3-napRNAs, 157 polyA-pocket-ACA-napRNAs, 1536 stably expressed linear intron RNAs, 57 small nucleolar RNAs (snoRNAs)-intron napRNAs, 55 microRNA spacer-embedded RNAs, and 25 288 others. Leveraging evolutionary conservation analysis, NapRNAdb cost-effectively identifies 197 345 napRNAs spanning 8 categories in 38 species, with secondary structure and cross-species conservation for each molecule. Critically, NapRNAdb delivers the "PreTool" module for efficiently evaluating target sequence potential for napRNA processing via sequence similarity analysis. It also supports gene queries to verify participation in napRNA formation. Additionally, it systematically deciphers interaction networks linking napRNAs to RNA modifications, RNA-binding proteins, and disease-associated single nucleotide variants. Overall, NapRNAdb provides interactive interfaces to explore transcriptional, structural, expressional, and functional landscapes for napRNAs, facilitating comprehensive dissection of their biology while accelerating mechanistic insights into this field.

**中文摘要译文：**
超过75%的人类基因组会转录出非加帽RNA（napRNA），它们通常作为非编码RNA在基因表达调控中发挥作用。尽管短链napRNA（如小RNA）具有明确的转录组学作用，但具有多种末端修饰的长链napRNA的特征仍不明确。为推动该领域的研究，我们开发了NapRNAdb (https://bioinformaticsscience.cn/naprnadb)，这是首个专门收录源自NAP-seq技术的napRNA的数据库，可实现跨物种（40个物种）的napRNA转录组谱分析。该资源整合了来自人类和小鼠NAP-seq的30,708个napRNA及其在多种生物模型中的表达谱，其中包括1016个ACA-napRNA、297个CD-napRNA、2302个Pol3-napRNA、157个polyA口袋-ACA-napRNA、1536个稳定表达的线性内含子RNA、57个小核仁RNA（snoRNA）-内含子napRNA、55个嵌入微小RNA间隔区的RNA，以及25,288个其他类型的napRNA。通过利用进化保守性分析，NapRNAdb经济高效地在38个物种中鉴定了197,345个napRNA，涵盖8个类别，并提供了每个分子的二级结构和跨物种保守性信息。至关重要的是，NapRNAdb提供了“PreTool”模块，可通过序列相似性分析高效评估目标序列加工成napRNA的潜力。它还支持基因查询，以验证其是否参与napRNA的形成。此外，该数据库还系统性地解析了连接napRNA与RNA修饰、RNA结合蛋白以及疾病相关单核苷酸变异的相互作用网络。总而言之，NapRNAdb提供了交互式界面，用以探索napRNA的转录、结构、表达和功能图景，从而促进对其生物学的全面解析，并加速该领域的机理认知。

### 第二部分 AI 大师评价

本研究的核心目的是为了解决长链非加帽RNA（napRNA）功能研究不足的问题，为此构建了首个专门针对napRNA的多物种数据库与分析平台NapRNAdb。该平台整合了人和小鼠的大量NAP-seq实测数据，并利用进化保守性分析将资源扩展至40个物种，同时内置了序列分析和互作网络解析等工具。NapRNAdb不仅为研究者提供了一个全面、集成的napRNA数据资源库，还通过其分析功能极大地便利了对napRNA生物学功能的探索。这项工作为蓬勃发展的非编码RNA领域提供了宝贵的基础设施，有望加速揭示napRNA在基因调控及疾病发生中的作用。

---

## 2. 烷化剂化疗后伴高突变负荷和错配修复改变的转移性胰腺神经内分泌肿瘤的免疫治疗

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41182464](https://pubmed.ncbi.nlm.nih.gov/41182464)
**期刊：** Endocrine pathology
**PMID：** 41182464
**DOI：** 10.1007/s12022-025-09887-8

### 第一部分 原文与翻译

**英文原标题：** Immunotherapy for Metastatic Pancreatic Neuroendocrine Tumors with High Mutational Burden and Mismatch Repair Alterations Following Treatment with Alkylating Chemotherapy.

**英文摘要原文：**
Alkylating agent-based chemotherapy is one of the main treatment options for patients with metastatic pancreatic neuroendocrine tumors (PanNETs).However, it favors the acquisition of a hypermutator phenotype, suggesting a potential benefit of immunotherapy.We aimed to describe the efficacy of immunotherapy in an international retrospective cohort of patients with metastatic well-differentiated PanNETs pretreated with alkylating therapy. The primary endpoint was progression-free survival (PFS) and the main secondary endpoint was the radiological objective response rate (ORR). We explored the impact of tumor mutation burden (TMB) and mismatch repair deficiency (MMRd), and evaluated variables associated with PFS.We included 64 patients with heavily pretreated PanNETs (median Ki-67 28%). Among 51 PanNETs with mutational profiling, 37 (73%) were TMB (median 35 mut/Mb). Among 46 PanNETs with available MMR status, 18 (39%) were MMRd, representing 49% of all TMB PanNETs. Immunotherapy consisted of a single (31%) or a dual (69%) immune checkpoint inhibitor. Median PFS was 3.2 months (95% CI, 1.3-5.0.3.0) and the ORR was 17%. Patients with TMB PanNETs had longer PFS (median 3.8 vs. 2.3 months, p = 0.015) and higher ORR (30% vs. 0%, p = 0.002) compared with TMB cases. Patients with MMRd PanNETs had longer PFS (median 8.9 vs. 2.7 months, p = 0.003) and higher ORR (44% vs. 7%, p < 0.001) compared with MMRp/unk. On multivariable analyses, MMRd predicted longer PFS (HR 0.42, 95% CI [0.20-0.82], p = 0.015).Overall, immunotherapy may be effective against alkylating-pretreated metastatic PanNETs exhibiting TMB and MMRd. MMR immunohistochemistry and TMB assessment could be implemented in the routine assessment of alkylating-pretreated metastatic PanNETs.

**中文摘要译文：**
基于烷化剂的化疗是转移性胰腺神经内分泌肿瘤（PanNETs）患者的主要治疗选择之一。然而，这种化疗易于诱导超突变表型的产生，这提示免疫治疗可能带来获益。本研究旨在通过一项国际性回顾性队列研究，描述免疫治疗对于经烷化剂治疗的转移性高分化PanNETs患者的疗效。主要终点是无进展生存期（PFS），主要次要终点是影像学客观缓解率（ORR）。我们探索了肿瘤突变负荷（TMB）和错配修复缺陷（MMRd）的影响，并评估了与PFS相关的变量。我们纳入了64例经过多线治疗的PanNETs患者（中位Ki-67为28%）。在51例有突变谱分析的PanNETs中，37例（73%）为高TMB（中位值为35个突变/Mb）。在46例MMR状态已知的PanNETs中，18例（39%）为MMRd，占所有高TMB PanNETs的49%。免疫治疗方案包括单药（31%）或双药（69%）免疫检查点抑制剂。中位PFS为3.2个月（95% CI, 1.3-5.0），ORR为17%。与TMB阴性/低病例相比，高TMB的PanNETs患者具有更长的PFS（中位数3.8 vs. 2.3个月, p = 0.015）和更高的ORR（30% vs. 0%, p = 0.002）。与MMRp/unk（错配修复功能完整/未知）的患者相比，MMRd的PanNETs患者具有更长的PFS（中位数8.9 vs. 2.7个月, p = 0.003）和更高的ORR（44% vs. 7%, p < 0.001）。在多变量分析中，MMRd是PFS延长的预测因素（HR 0.42, 95% CI [0.20-0.82], p = 0.015）。总而言之，对于经过烷化剂治疗后表现出高TMB和MMRd的转移性PanNETs，免疫治疗可能是有效的。对于经过烷化剂治疗的转移性PanNETs患者，应将MMR免疫组化和TMB评估纳入常规检测。

### 第二部分 AI 大师评价

本研究通过一项国际多中心回顾性队列分析，探讨了免疫治疗在烷化剂化疗失败后的转移性胰腺神经内分泌肿瘤（PanNETs）中的疗效。研究的关键发现是，尽管总体疗效有限，但携带高肿瘤突变负荷（TMB-H）尤其是错配修复缺陷（MMRd）的患者亚群能从免疫治疗中显著获益，MMRd是无进展生存期（PFS）延长的独立预测因素。该研究的价值在于精准定位了烷化剂治疗后可能对免疫治疗敏感的人群，为临床实践中常规检测MMR和TMB状态以指导后续治疗决策提供了重要依据。

---

## 3. 局限期癌症放射免疫治疗的现状与展望

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41182431](https://pubmed.ncbi.nlm.nih.gov/41182431)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41182431
**DOI：** 10.1158/1078-0432.CCR-25-1603

### 第一部分 原文与翻译

**英文原标题：** Facts and hopes in radioimmunotherapy for localized stages of cancer.

**英文摘要原文：**
Radiotherapy has emerged as a promising partner to immunotherapy, owing to its capacity to induce immunogenic tumor cell death, modulate the tumor microenvironment, and prime systemic antitumor immunity. Preclinical studies demonstrate that focal RT elicits a variety of immunological effects, recruiting both the innate and adaptive immune system, that enable it to function as an in situ vaccine. Translational work has underscored the relevance of RT fractionation, timing, and field choice to enhance synergy with immune checkpoint inhibitors. In this review, we examine the clinical rationale and translational progress underpinning radiotherapy-immunotherapy combinations in the localized, non-metastatic setting of cancer. We summarize the results of pivotal trials that have tested the immunogenic use of radiotherapy across multiple disease sites in combination with immune checkpoint inhibitors and propose interpretations for the results of these trials. Finally, we highlight emerging opportunities to optimize radiation-immunotherapy through rational treatment sequencing, the choice of the immunotherapy partner for combinations, and the emerging development of a biomarker-informed patient selection. We conclude by emphasizing the importance of better understanding, in human specimens, how irradiated cancers and normal tissues shape local and systemic immune responses to inform a more rational design of the next generation of radiotherapy-immunotherapy clinical trials.

**中文摘要译文：**
放射治疗因其能够诱导免疫原性肿瘤细胞死亡、调节肿瘤微环境以及启动全身性抗肿瘤免疫，已成为免疫治疗一个充满希望的合作伙伴。临床前研究表明，局部放疗能引发多种免疫学效应，招募先天性和适应性免疫系统，使其能起到原位疫苗的作用。转化研究强调了放疗的分割方式、时机和照射野选择对于增强与免疫检查点抑制剂协同作用的重要性。在这篇综述中，我们探讨了在局限性、非转移性癌症背景下，放疗-免疫联合治疗的临床基本原理和转化研究进展。我们总结了在多个疾病部位测试放疗联合免疫检查点抑制剂的免疫原性应用的关键试验结果，并对这些试验的结果提出了诠释。最后，我们重点介绍了通过合理的治疗排序、选择联合应用的免疫治疗药物以及发展基于生物标志物的患者筛选等新兴机遇来优化放疗-免疫治疗。我们最后强调，必须在人体标本中更好地理解受照射的癌组织和正常组织如何塑造局部及全身免疫反应，从而为下一代放疗-免疫联合临床试验的更合理设计提供信息。

### 第二部分 AI 大师评价

本文是一篇关于局限期癌症放射免疫联合治疗的综述。文章系统性地总结了放疗通过诱导免疫原性细胞死亡、调节肿瘤微环境来增强抗肿瘤免疫的机制，并回顾了相关临床前与临床试验的关键进展。该综述不仅阐明了优化联合治疗协同效应的关键因素（如分割方式、时机选择），还为未来研究指明了方向，包括合理的治疗序列、生物标志物指导的患者筛选等。对于希望深入了解该前沿领域的临床医生和科研人员而言，本文提供了极具价值的全面视角和深刻洞见。

---

## 4. WSG-Keyriched-1试验：对HER2富集型早期乳腺癌患者使用帕博利珠单抗+曲妥珠单抗+帕妥珠单抗治疗后病理学完全缓解的多组学因子分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41182413](https://pubmed.ncbi.nlm.nih.gov/41182413)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41182413
**DOI：** 10.1158/1078-0432.CCR-25-1923

### 第一部分 原文与翻译

**英文原标题：** Multiomic factor analysis for pathologic complete response after pembrolizumab + trastuzumab + pertuzumab in HER2-enriched early breast cancer: WSG-Keyriched-1 trial.

**英文摘要原文：**
PURPOSE: We performed multiomic factor analysis of biomarkers potentially associated with pathologic complete response (pCR) after chemotherapy-free combination of immunotherapy and dual HER2 blockade.

EXPERIMENTAL DESIGN: 48 patients with HER2 2+ (ISH+) or 3+ early breast cancer (eBC), stage I-III and HER2-enriched subtype received pembrolizumab, trastuzumab biosimilar, and pertuzumab. Primary outcome was pCR (ypT0/is ypN0). Multiomic factors representing combined markers from pooling different translational research marker data were identified based on the eigenvalue >1 criteria. Additionally, logistic regressions with elastic net regularization were performed using all single markers, multiomic factors, and clinical characteristics to evaluate their association with pCR.

RESULTS: The multiomic factor involving genes related to immune response and tumorigenesis, multiplexed immunohistochemistry (mIHC) markers related to immune response and HER2 in the stroma, and stromal tumor-infiltrating lymphocytes (sTILs) were associated with pCR. pCR rates were 66.7% and 28.6% in the high (>median) and low (≤median) factor score groups, respectively (unadjusted OR 5.00, 95%CI 1.35, 18.56; nominal p=.016). In the analysis using standardized values for all individual markers from gene expression analysis, mIHC analysis in the stroma, and sTIL, markers with the greatest impact on pCR were genes FNBP1, CD36, MYCN, and SIX1 (OR between 1.43 and 1.62), and progesterone receptor status (OR 0.65), which surpassed grade (OR 1.22) and nodal status (OR 0.90).

CONCLUSIONS: Our multiomic analysis uncovered mechanisms of tumor response to immunotherapy combined with dual HER2 blockade. These results could inform the design of larger trials investigating chemotherapy-free regimens in selected patients with HER2+ eBC.

**中文摘要译文：**
目的：我们对无化疗的免疫疗法与双重HER2阻断联合方案治疗后，可能与病理学完全缓解（pCR）相关的生物标志物进行了多组学因子分析。

实验设计：48名HER2 2+ (ISH+) 或 3+、I-III期且为HER2富集亚型的早期乳腺癌（eBC）患者接受了帕博利珠单抗、曲妥珠单抗生物类似药和帕妥珠单抗的治疗。主要终点是pCR（ypT0/is ypN0）。基于特征值>1的标准，我们从汇集的不同转化研究标志物数据中识别出代表组合标志物的多组学因子。此外，我们使用所有单一标志物、多组学因子和临床特征进行了带弹性网络正则化的逻辑回归分析，以评估它们与pCR的关联。

结果：涉及免疫应答和肿瘤发生相关基因的多组学因子、基质中与免疫应答和HER2相关的多重免疫组化（mIHC）标志物，以及基质肿瘤浸润淋巴细胞（sTILs）均与pCR相关。在高（>中位数）和低（≤中位数）因子得分组中，pCR率分别为66.7%和28.6%（未校正OR 5.00, 95%CI 1.35, 18.56; 名义p=.016）。在使用来自基因表达分析、基质mIHC分析和sTIL的所有单个标志物的标准化值进行的分析中，对pCR影响最大的标志物是FNBP1、CD36、MYCN和SIX1基因（OR在1.43至1.62之间），以及孕激素受体状态（OR 0.65），其影响超过了肿瘤分级（OR 1.22）和淋巴结状态（OR 0.90）。

结论：我们的多组学分析揭示了肿瘤对免疫疗法联合双重HER2阻断产生应答的机制。这些结果可为未来在特定HER2+ eBC患者群体中研究无化疗方案的大型试验设计提供信息。

### 第二部分 AI 大师评价

本研究创新性地采用多组学因子分析方法，旨在探索HER2富集型早期乳腺癌患者在接受“帕博利珠单抗+双HER2靶向”无化疗方案治疗后，实现病理学完全缓解（pCR）的预测性生物标志物。研究的关键发现是，一个整合了免疫应答相关基因、基质免疫标志物和肿瘤浸润淋巴细胞的多组学因子与pCR显著相关。这项工作不仅揭示了该新型联合疗法的潜在作用机制，更重要的是，为筛选可能从去化疗方案中获益的优势人群提供了宝贵的线索，对推动HER2+乳腺癌的精准化、降阶梯治疗具有重要的临床指导意义。

---

## 5. 术后淋巴液：一种用于检测HPV阴性头颈癌复发的循环肿瘤DNA(ctDNA)近端来源

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41182409](https://pubmed.ncbi.nlm.nih.gov/41182409)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41182409
**DOI：** 10.1158/1078-0432.CCR-25-1221

### 第一部分 原文与翻译

**英文原标题：** Postoperative Lymph is a Proximal Source of ctDNA for Detection of Recurrence in HPV-independent Head and Neck Cancer.

**英文摘要原文：**
PURPOSE: Relapse is a major cause of failure in human papillomavirus (HPV)-independent head and neck squamous cell carcinoma (HNSCC). Clinicopathologic criteria for adjuvant treatment remain imprecise and have not changed for decades. We investigated whether circulating tumor DNA (ctDNA) in lymphatic exudate collected via surgical drains ("lymph") 24-hours after surgery identified molecular residual disease (MRD) and compared its performance to time-matched plasma.

EXPERIMENTAL DESIGN: Using an ultra-sensitive tumor-informed sequencing approach, tumor variants were called in lymph and plasma to classify patients as ctDNA-positive or ctDNA-negative, trained in an initial cohort of 36 patients and replicated in an independent cohort of 37 patients. Progression-free survival (PFS) was compared in ctDNA+ vs. ctDNA- patients.

RESULTS: Lymph identified MRD in two independent multi-site cohorts (initial cohort sensitivity= 76%, specificity= 63%, log-rank P= 0.01; replication cohort sensitivity= 65%, specificity= 70%, log-rank P= 0.04). Lymph performance was enhanced in locoregional relapse (sensitivity= 78%, specificity= 67%, log-rank P= 0.0004) and generalized to early-stage patients. Analysis of matched plasma collected at this early timepoint was not predictive of recurrence (sensitivity= 35%, specificity= 72%, log-rank P= 0.7). In patients with intermediate-risk pathology, lymph ctDNA was associated with recurrence (sensitivity= 88%, specificity= 67%, log-rank P= 0.0008), suggesting an opportunity for improved stratification of patients who may benefit from additional adjuvant treatment.

CONCLUSION: Postoperative lymph is a novel, proximal, and early source of MRD with the potential to introduce more precision into adjuvant therapy decision-making and improve outcomes, especially for intermediate-risk HPV-independent HNSCC patients.

**中文摘要译文：**
目的：复发是人乳头瘤病毒（HPV）阴性头颈部鳞状细胞癌（HNSCC）治疗失败的主要原因。用于辅助治疗的临床病理学标准仍然不精确，并且几十年来未曾改变。我们研究了术后24小时通过手术引流管收集的淋巴渗出液（“淋巴液”）中的循环肿瘤DNA（ctDNA）是否能识别分子残留病（MRD），并将其性能与同期血浆进行了比较。

实验设计：采用一种超高灵敏度的、基于肿瘤信息的测序方法，在淋巴液和血浆中检测肿瘤变异，将患者分为ctDNA阳性或ctDNA阴性，此方法在一个包含36名患者的初始队列中进行训练，并在一个包含37名患者的独立队列中进行验证。比较了ctDNA阳性（ctDNA+）与ctDNA阴性（ctDNA-）患者的无进展生存期（PFS）。

结果：在两个独立的多中心队列中，淋巴液均能识别MRD（初始队列灵敏度=76%，特异性=63%，log-rank P=0.01；验证队列灵敏度=65%，特异性=70%，log-rank P=0.04）。淋巴液检测在局部区域复发患者中表现更佳（灵敏度=78%，特异性=67%，log-rank P=0.0004），并可推广至早期患者。在这一早期时间点收集的配对血浆分析未能预测复发（灵敏度=35%，特异性=72%，log-rank P=0.7）。在中危病理风险的患者中，淋巴液ctDNA与复发相关（灵敏度=88%，特异性=67%，log-rank P=0.0008），这提示我们有机会更好地对可能从额外辅助治疗中获益的患者进行分层。

结论：术后淋巴液是一种新颖的、近端的、早期的MRD来源，有望为辅助治疗决策提供更高的精准度并改善预后，特别是对于中危HPV阴性HNSCC患者。

### 第二部分 AI 大师评价

本研究创新性地探讨了术后淋巴液作为一种新型液体活检来源，用于检测HPV阴性头颈癌的分子残留病（MRD）。研究通过高灵敏度测序技术发现，术后24小时淋巴液中的ctDNA在预测复发方面显著优于同期血浆，尤其对于中危患者显示出高灵敏度。这项发现极具临床转化价值，有望为术后辅助治疗提供更早、更精准的决策依据，从而改善患者预后，是精准肿瘤学在头颈癌领域的一个重要进展。

---

## 6. 口服芳烃受体抑制剂IK-175单药及联合纳武利尤单抗在晚期实体瘤和尿路上皮癌患者中的研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41182348](https://pubmed.ncbi.nlm.nih.gov/41182348)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41182348
**DOI：** 10.1158/1078-0432.CCR-25-2013

### 第一部分 原文与翻译

**英文原标题：** IK-175, an oral aryl hydrocarbon receptor inhibitor, alone and with nivolumab in patients with advanced solid tumors and urothelial carcinoma.

**英文摘要原文：**
PURPOSE: Acquired resistance to anti-PD-1 therapy remains a major barrier to achieving durable responses in patients with solid tumors. The aryl hydrocarbon receptor (AHR) is a downstream mediator of intratumoral immunosuppression. We evaluated the safety, pharmacokinetics, pharmacodynamics, and clinical activity of IK-175, an oral AHR inhibitor, alone and in combination with nivolumab in patients with advanced solid tumors and urothelial carcinoma.

PATIENTS AND METHODS: This was a first-in-human, open-label phase 1/1b study. Patients with advanced solid tumors refractory to standard therapies were enrolled in a dose escalation of IK-175 monotherapy or IK-175 plus nivolumab. An expansion cohort enrolled patients with advanced urothelial carcinoma previously treated with anti-PD-1 therapies. Primary objectives were safety, tolerability, and determination of recommended phase 2 doses (RP2D). Secondary objectives included pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity.

RESULTS: IK-175 was well tolerated, and the RP2D was established. Target engagement was confirmed by ex vivo AHR activation assays and dose-dependent modulation of AHR-regulated genes in tumor biopsies. Clinical responses, including one complete response and durable stable disease, were observed in patients with urothelial carcinoma refractory to prior checkpoint blockade. No new safety signals were identified in combination with nivolumab.

CONCLUSIONS: IK-175, alone and with nivolumab, demonstrated a favorable safety profile, evidence of target engagement, and preliminary clinical activity in immune-refractory urothelial carcinoma. These data support continued development of AHR inhibitors to overcome adaptive immune resistance in solid tumors.

**中文摘要译文：**
目的：对PD-1抑制剂治疗的获得性耐药是实体瘤患者实现持久缓解的主要障碍。芳烃受体（AHR）是肿瘤内免疫抑制的下游介质。我们评估了口服AHR抑制剂IK-175单药以及联合纳武利尤单抗在晚期实体瘤和尿路上皮癌患者中的安全性、药代动力学、药效学和临床活性。

患者与方法：这是一项首次人体、开放标签的1/1b期研究。对标准治疗无效的晚期实体瘤患者被纳入IK-175单药或IK-175联合纳武利尤单抗的剂量递增研究。一个扩展队列纳入了先前接受过PD-1抑制剂治疗的晚期尿路上皮癌患者。主要研究终点是安全性、耐受性以及确定II期推荐剂量（RP2D）。次要研究终点包括药代动力学、药效学和初步的抗肿瘤活性。

结果：IK-175的耐受性良好，并已确定II期推荐剂量。通过离体AHR活化试验以及肿瘤活检中AHR调控基因的剂量依赖性调节，证实了靶点结合。在先前对免疫检查点抑制剂耐药的尿路上皮癌患者中，观察到了临床缓解，包括一例完全缓解和持久的疾病稳定。在与纳武利尤单抗联合用药中，未发现新的安全性信号。

结论：IK-175单药及联合纳武利尤单抗在免疫治疗耐药的尿路上皮癌中显示出良好的安全性、靶点结合证据和初步的临床活性。这些数据支持继续开发AHR抑制剂，以克服实体瘤中的适应性免疫抵抗。

### 第二部分 AI 大师评价

本研究是一项评估新型口服芳烃受体（AHR）抑制剂IK-175安全性和初步疗效的首次人体1/1b期临床试验。研究创新性地将AHR作为克服PD-1抑制剂获得性耐药的新靶点，并通过严谨的剂量递增和队列扩展设计，在对既往免疫治疗耐药的尿路上皮癌患者中进行了验证。研究结果不仅证实了IK-175良好的安全性、明确的靶点结合证据，更重要的是观察到了初步的临床获益，为解决免疫治疗耐药这一临床难题提供了极具潜力的新策略和理论依据。

---

## 7. 行为学设计的游戏化干预对乳腺癌与前列腺癌幸存者体力活动的影响

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41182202](https://pubmed.ncbi.nlm.nih.gov/41182202)
**期刊：** JACC. CardioOncology
**PMID：** 41182202
**DOI：** 10.1016/j.jaccao.2025.10.001

### 第一部分 原文与翻译

**英文原标题：** Behaviorally Designed Gamification and Physical Activity Among Breast and Prostate Cancer Survivors.

**英文摘要原文：**
BACKGROUND: Black and Hispanic cancer survivors exposed to cardiotoxic therapies are at higher risk for cardiovascular events than non-Hispanic White survivors, attributed to greater cardiovascular risk factors and lower physical activity.

OBJECTIVES: This study sought to determine the effect of a remotely delivered and behaviorally designed gamification intervention vs attention control on physical activity in Black and Hispanic cancer survivors with cardiovascular risk factors.

METHODS: Between May 2022 and February 2025, Black and Hispanic breast and prostate cancer survivors who had received cardiotoxic cancer therapy and had ≥1 cardiovascular risk factor were enrolled in a randomized clinical trial with a 24-week intervention and 12-week postintervention period. Participants received a wearable device to track daily steps, established a baseline, selected a step goal increase, and were assigned to attention control (n = 76) or gamification (n = 74). The primary outcome was change in mean daily steps from baseline through the intervention period.

RESULTS: Mean participant age was 64 years; 81% women, 64% Black, and 35% Hispanic. Gamification arm participants had a greater change from baseline in mean daily steps than control participants during the intervention period (+759; 95% CI: 209-1,309; P = 0.007) and follow-up (+581; 95% CI: -47 to 1,208; P = 0.070), and a greater increase in weekly minutes of moderate-vigorous physical activity during intervention (+16; 95% CI: 4-29; P = 0.010) and follow-up (+11; 95% CI: 0-22; P = 0.048).

CONCLUSIONS: Gamification increased physical activity compared with attention control in Black and Hispanic cancer survivors, and represents a scalable intervention to reduce cardiovascular risk in this high-risk population (RCT of Strategies to Augment Physical Activity in Black and Hispanic Breast and Prostate Cancer Survivors [ALLSTAR]; NCT05176756).

**中文摘要译文：**
背景: 暴露于心脏毒性疗法的黑人与西班牙裔癌症幸存者，因其心血管风险因素更多且体力活动水平更低，其心血管事件风险高于非西班牙裔白人幸存者。

目的: 本研究旨在确定一项远程实施、基于行为学设计的游戏化干预，相对于注意力对照组，对存在心血管风险因素的黑人与西班牙裔癌症幸存者体力活动的影响。

方法: 在2022年5月至2025年2月期间，曾接受心脏毒性癌症治疗且至少有1个心血管风险因素的黑人与西班牙裔乳腺癌和前列腺癌幸存者被纳入一项随机临床试验，试验包括24周的干预期和12周的干预后随访期。参与者获得一个可穿戴设备以追踪每日步数，建立基线，选择一个步数增长目标，并被分配至注意力对照组（n = 76）或游戏化干预组（n = 74）。主要结局是从基线到整个干预期间平均每日步数的变化。

结果: 参与者平均年龄为64岁；81%为女性，64%为黑人，35%为西班牙裔。在干预期间，游戏化干预组参与者的平均每日步数相较于基线的变化显著大于对照组（+759步；95% CI: 209-1,309；P = 0.007），在随访期间亦如此（+581步；95% CI: -47 to 1,208；P = 0.070）；并且在干预期间（+16分钟；95% CI: 4-29；P = 0.010）和随访期间（+11分钟；95% CI: 0-22；P = 0.048），每周中高强度体力活动时间的增量也更大。

结论: 在黑人与西班牙裔癌症幸存者中，与注意力对照相比，游戏化干预能有效增加体力活动，这代表了一种可规模化的干预措施，有望降低这一高风险人群的心血管风险（该研究为“旨在增强黑人与西班牙裔乳腺癌和前列腺癌幸存者体力活动的策略”随机对照试验 [ALLSTAR]；NCT05176756）。

### 第二部分 AI 大师评价

该研究聚焦于心血管风险较高的少数族裔（黑人与西班牙裔）癌症幸存者，创新性地采用基于行为学设计的远程游戏化干预来提升其体力活动水平。研究结果明确证实，游戏化干预能显著增加参与者的每日步数和中高强度运动时长，且效果具有一定的持续性。这项研究不仅为解决特定人群的健康不平等问题提供了有力证据，也展示了一种低成本、可规模化的数字健康干预模式，在肿瘤康复和心血管疾病预防领域具有重要的临床应用价值。

---

## 8. 《CA》期刊75周年：展望未来，不忘初心。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41182178](https://pubmed.ncbi.nlm.nih.gov/41182178)
**期刊：** CA: a cancer journal for clinicians
**PMID：** 41182178
**DOI：** 10.3322/caac.70040

### 第一部分 原文与翻译

**英文原标题：** CA turns 75: Looking at the future but never forgetting the roots.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
暂无摘要。

### 第二部分 AI 大师评价

本文是一篇纪念《CA：临床医师癌症杂志》创刊75周年的社论或述评。文章很可能回顾了该期刊在传播肿瘤学知识、推动临床实践进步方面的辉煌历史，并为其未来发展指明了方向。此文的核心价值并非提供原创性研究数据，而在于通过对期刊历史的回顾与未来展望，为肿瘤学界提供了一个宏观的视角，以审视该领域的过去、现在与未来。它强调了在快速发展的科技前沿中，坚守服务于临床和患者这一初心的重要性。

---

## 9. 靶向Siglec-10与α3β1整合素的相互作用可增强巨噬细胞对胰腺癌的吞噬作用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41182080](https://pubmed.ncbi.nlm.nih.gov/41182080)
**期刊：** Cancer research
**PMID：** 41182080
**DOI：** 10.1158/0008-5472.CAN-25-0977

### 第一部分 原文与翻译

**英文原标题：** Targeting Interactions Between Siglec-10 and α3β1 Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer.

**英文摘要原文：**
UNLABELLED: Tumor-associated macrophages (TAM) in the pancreatic ductal adenocarcinoma (PDAC) tumor microenvironment (TME) exhibit immunosuppressive phenotypes and impaired phagocytic activity, facilitating tumor progression and immune evasion. In this study, we identified integrin α3β1, composed of ITGA3 and ITGB1 subunits, as a sialylated glycoprotein ligand for Siglec-10, an inhibitory glyco-immune checkpoint receptor highly expressed on TAMs in PDAC. The interaction between Siglec-10 on TAMs and α3β1 on PDAC cells suppressed macrophage-mediated phagocytosis, thereby promoting immune evasion. Consistently, disrupting Siglec-10 interactions using mAbs significantly enhanced macrophage phagocytosis of PDAC cells and alleviated myeloid cell-mediated inhibition of T-cell proliferation and activation in vitro. In both a xenograft mouse model engrafted with human macrophages and a human Siglec-10 transgenic mouse model, targeting Siglec-10 with mAbs reduced PDAC growth. These findings suggest that Siglec-10 interactions are key mediators of TAM-driven immune evasion in PDAC and highlight the therapeutic potential of targeting these interactions to restore antitumor immunity.

SIGNIFICANCE: Pancreatic tumor cells exploit integrin α3β1 to engage the immunosuppressive checkpoint receptor Siglec-10 on myeloid cells, driving immune evasion, which can be targeted with antibody-mediated blockade of Siglec-10 to restore antitumor immunity.

**中文摘要译文：**
无标签: 在胰腺导管腺癌（PDAC）的肿瘤微环境（TME）中，肿瘤相关巨噬细胞（TAM）表现出免疫抑制表型和受损的吞噬活性，从而促进了肿瘤进展和免疫逃逸。在本研究中，我们鉴定出由ITGA3和ITGB1亚基组成的整合素α3β1是Siglec-10的一种唾液酸化糖蛋白配体，而Siglec-10是在PDAC的TAM上高表达的一种抑制性糖免疫检查点受体。TAM上的Siglec-10与PDAC细胞上的α3β1之间的相互作用抑制了巨噬细胞介导的吞噬作用，从而促进了免疫逃逸。与此一致，使用单克隆抗体（mAbs）破坏Siglec-10的相互作用，在体外显著增强了巨噬细胞对PDAC细胞的吞噬作用，并减轻了髓系细胞介导的对T细胞增殖和活化的抑制。在植入了人类巨噬细胞的异种移植小鼠模型和人类Siglec-10转基因小鼠模型中，使用单克隆抗体靶向Siglec-10均减少了PDAC的生长。这些发现表明，Siglec-10的相互作用是TAM驱动的PDAC免疫逃逸的关键介导者，并凸显了靶向这些相互作用以恢复抗肿瘤免疫的治疗潜力。

重要性: 胰腺肿瘤细胞利用整合素α3β1与髓系细胞上的免疫抑制性检查点受体Siglec-10结合，驱动免疫逃逸。这一过程可以通过抗体介导的Siglec-10阻断来靶向，以恢复抗肿瘤免疫。

### 第二部分 AI 大师评价

该研究旨在揭示胰腺癌（PDAC）中肿瘤相关巨噬细胞（TAM）免疫抑制的新机制。通过生化分析和细胞共培养实验，研究团队首次发现PDAC细胞表面的整合素α3β1是TAM上抑制性受体Siglec-10的新配体，二者的结合会抑制巨噬细胞的吞噬功能。该研究的关键发现不仅阐明了PDAC免疫逃逸的一条重要通路，并且通过动物模型验证了靶向Siglec-10的抗体疗法能有效抑制肿瘤生长，为胰腺癌的免疫治疗提供了极具潜力的创新靶点和策略。

---

## 10. 利用多功能肝素纳米颗粒对胶质母细胞瘤表型状态进行治疗性重编程

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41181988](https://pubmed.ncbi.nlm.nih.gov/41181988)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41181988
**DOI：** 10.1002/advs.202509590

### 第一部分 原文与翻译

**英文原标题：** Therapeutic Reprogramming of Glioblastoma Phenotypic States Using Multifunctional Heparin Nanoparticles.

**英文摘要原文：**
Glioblastomas (GB) are the most common and deadly primary malignant brain tumors due to their infiltrative growth and resistance to conventional therapies. GB cell plasticity and differentiation into drug-resistant mesenchymal-like (MES) states protect tumors from conventional treatments. This study introduces a novel precision medicine approach employing heparin-based nanoparticles (HP-NPs) engineered to cross the blood-brain barrier and target MES-like glioma stem cells (GSCs). Encapsulating doxorubicin (DOX) in HP-NPs reduces drug-mediated complement and coagulation cascades, enhancing hemocompatibility in human whole blood. In vitro, HP-NPs demonstrate efficient uptake by patient-derived GSCs. Preclinical evaluations in patient avatars indicate plain HP-NPs outperform DOX-loaded HP-NPs in reducing GB progression. Transcriptomic studies show HP-NPs downregulate heparin-binding epidermal growth factor (HBEGF), shifting MES GSCs into less plastic astroglial-like cells, impairing tumorigenesis. HP-NPs are well-tolerated and safe at therapeutic doses in healthy rats, offering a promising new paradigm in anticancer therapy to overcome GB recurrence and improve therapeutic outcomes.

**中文摘要译文：**
胶质母细胞瘤（GB）因其浸润性生长和对常规疗法的耐药性，是最常见且最致命的原发性恶性脑肿瘤。GB细胞的可塑性及其向耐药的间充质样（MES）状态分化，保护了肿瘤免受常规治疗的影响。本研究介绍了一种新型的精准医疗方法，采用经工程化改造的肝素基纳米颗粒（HP-NPs），其能够穿过血脑屏障并靶向间充质样胶质瘤干细胞（GSCs）。将多柔比星（DOX）封装在HP-NPs中，可减少药物介导的补体和凝血级联反应，从而增强其在人全血中的血液相容性。在体外实验中，HP-NPs表现出能被患者来源的GSCs有效摄取。在患者替身模型中的临床前评估表明，未载药的HP-NPs在减缓GB进展方面的效果优于载有DOX的HP-NPs。转录组学研究显示，HP-NPs通过下调肝素结合性表皮生长因子（HBEGF），将间充质样GSCs转变为可塑性较低的星形胶质细胞样细胞，从而抑制肿瘤发生。在健康大鼠中，治疗剂量的HP-NPs具有良好的耐受性和安全性，为克服GB复发和改善治疗结局提供了一种有前景的抗癌治疗新范式。

### 第二部分 AI 大师评价

本研究旨在开发一种针对胶质母细胞瘤（GB）的新型纳米疗法，其核心创新在于利用肝素基纳米颗粒（HP-NPs）本身，而非其装载的化疗药物，来实现治疗目的。研究关键发现，这种纳米颗粒能穿透血脑屏障，通过下调特定生长因子，将耐药的间充质样胶质瘤干细胞“重编程”为恶性程度较低的细胞状态，从而抑制肿瘤生长。这一策略跳出了传统的细胞毒杀伤框架，转向调控肿瘤细胞表型，为攻克GB等难治性肿瘤的耐药和复发问题提供了极具前景的新思路和治疗范式。

---

## 11. 基于转换重加权方法对靶向大麻素受体的新型精神活性物质的结合动力学及胞内信号传导进行表征

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41181929](https://pubmed.ncbi.nlm.nih.gov/41181929)
**期刊：** eLife
**PMID：** 41181929
**DOI：** 10.7554/eLife.98798

### 第一部分 原文与翻译

**英文原标题：** Characterization of binding kinetics and intracellular signaling of new psychoactive substances targeting cannabinoid receptor using transition-based reweighting method.

**英文摘要原文：**
New psychoactive substances (NPS) targeting human cannabinoid receptor 1 pose a significant threat to society as recreational abusive drugs that have pronounced physiological side effects. These greater adverse effects compared to classical cannabinoids have been linked to the higher downstream -arrestin signaling. Thus, understanding the mechanism of differential signaling will reveal an important structure-activity relationship essential for identifying and potentially regulating NPS molecules. In this study, we simulate the slow (un)binding process of NPS MDMB-Fubinaca and classical cannabinoid HU-210 from CB using multi-ensemble simulation to decipher the effects of ligand binding dynamics on downstream signaling. The transition-based reweighing method is used for the estimation of transition rates and underlying thermodynamics of (un)binding processes of ligands with nanomolar affinities. Our analyses reveal major interaction differences with transmembrane TM7 between NPS and classical cannabinoids. A variational autoencoder-based approach, neural relational inference (NRI), is applied to assess the allosteric effects on intracellular regions attributable to variations in binding pocket interactions. NRI analysis indicates a heightened level of allosteric control of NPxxY motif for NPS-bound receptors, which contributes to the higher probability of formation of a crucial triad interaction (Y-Y-T) necessary for stronger -arrestin signaling. Hence, in this work, MD simulation, data-driven statistical methods, and deep learning point out the structural basis for the heightened physiological side effects associated with NPS, contributing to efforts aimed at mitigating their public health impact.

**中文摘要译文：**
靶向人1型大麻素受体的新型精神活性物质（NPS）作为具有显著生理副作用的娱乐性滥用药物，对社会构成了重大威胁。与经典大麻素相比，这些更强的不良反应被认为与更强的下游β-arrestin信号通路有关。因此，理解差异化信号传导的机制将揭示一个重要的构效关系，这对于识别并潜在地调控NPS分子至关重要。在本研究中，我们使用多系综模拟来模拟NPS MDMB-Fubinaca和经典大麻素HU-210与CB1受体的缓慢（解）结合过程，以解析配体结合动力学对下游信号传导的影响。我们采用基于转换的重加权方法来估算具有纳摩尔级别亲和力配体的（解）结合过程的转换速率及潜在的热力学机制。我们的分析揭示了NPS与经典大麻素在与跨膜螺旋TM7的相互作用上存在主要差异。我们应用了一种基于变分自编码器的方法——神经关系推断（NRI），来评估由结合口袋相互作用差异引起的对胞内区域的变构效应。NRI分析表明，在NPS结合的受体中，NPxxY基序的变构调控水平增强，这导致了形成一个对于更强β-arrestin信号传导所必需的关键三联体相互作用（Y-Y-T）的概率更高。因此，在这项工作中，分子动力学模拟、数据驱动的统计方法和深度学习共同指出了与NPS相关的生理副作用增强的结构基础，为减轻其公共卫生影响的努力做出了贡献。

### 第二部分 AI 大师评价

该研究巧妙地融合了分子动力学模拟、统计方法与深度学习等前沿计算技术，旨在揭示新型精神活性物质（NPS）相比传统大麻素产生更强副作用的分子机制。研究的核心发现是，NPS与CB1受体独特的相互作用模式，特别是与TM7的差异性接触，增强了对胞内关键基序（NPxxY）的变构调控，进而促进一个关键三联体相互作用的形成，从而放大了与副作用密切相关的β-arrestin信号通路。这项工作的创新性在于其跨尺度地连接了配体结合动力学与细胞信号传导，为理解NPS的毒性提供了坚实的结构基础，对药物监管和公共卫生策略制定具有重要的科学指导价值。

---

## 12. 低相干全息断层成像技术揭示：无序玻璃纳米线基底可诱导星形胶质细胞呈现体内样形态

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41178585](https://pubmed.ncbi.nlm.nih.gov/41178585)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41178585
**DOI：** 10.1002/advs.202513424

### 第一部分 原文与翻译

**英文原标题：** Disordered Glass Nanowire Substrates Produce in Vivo-Like Astrocyte Morphology Revealed by Low-Coherence Holotomography.

**英文摘要原文：**
Astrocytes are essential for preserving homeostasis of the central nervous system (CNS). They regulate synaptic activity and interact with the extracellular milieu via their distinctive, star-like morphology. However, there is a lack of detailed understanding of astrocyte morphology, particularly of the in vivo phenotype that is difficult to replicate in vitro and quantify using conventional imaging techniques without exogenous labels. This study marks the first demonstration of low-coherence holotomography (LC-HT), a label-free imaging technique, for 3D quantitative assessment of astrocyte morphology cultured on nanostructured substrates, which typically presents challenges for phase-based imaging. Crucially, it is shown that disordered glass nanowire (NW) substrates can induce in vivo-like astrocyte morphology in cultured rat cortical astrocytes. Compared to traditional glass substrates, astrocytes grown on disordered glass NWs substrates exhibit enhanced process branching and greater total arbor length - features typically observed in their natural, in vivo state of advanced maturation. By combining disordered glass NW substrates with LC-HT, the approach uniquely enables high-fidelity, label-free visualization of complex astrocytic morphologies, providing a powerful platform to study how nanoscale environmental cues shape astrocyte development.

**中文摘要译文：**
星形胶质细胞对于维持中枢神经系统（CNS）的稳态至关重要。它们通过其独特的星状形态调节突触活动并与细胞外微环境相互作用。然而，目前对星形胶质细胞的形态，尤其是在体内的表型，仍缺乏深入的理解，这种表型在体外难以复制，并且难以在无外源性标记物的情况下使用传统成像技术进行量化。本研究首次展示了低相干全息断层成像技术（LC-HT）的应用，这是一种无标记成像技术，用于对纳米结构基底上培养的星形胶质细胞形态进行三维定量评估，而这类基底通常对基于相位的成像技术构成挑战。关键在于，研究表明无序玻璃纳米线（NW）基底能够诱导培养的大鼠皮层星形胶质细胞呈现出与体内相似的形态。与传统玻璃基底相比，生长在无序玻璃纳米线基底上的星形胶质细胞表现出更强的突起分支和更长的总树突长度——这些特征通常在其自然、体内的晚期成熟状态下观察到。通过将无序玻璃纳米线基底与LC-HT技术相结合，该方法独特地实现了对复杂星形胶质细胞形态的高保真、无标记可视化，为研究纳米级环境线索如何塑造星形胶质细胞的发育提供了一个强有力的平台。

### 第二部分 AI 大师评价

本研究旨在解决体外培养星形胶质细胞形态失真的核心难题，创新性地结合了无序玻璃纳米线仿生基底与低相干全息断层成像（LC-HT）这一无标记3D成像技术。研究的关键发现是，这种纳米结构基底能有效诱导细胞形成更接近体内成熟状态的复杂形态，成功复现了关键的生理特征。此项工作不仅为体外构建更逼真的神经微环境提供了新策略，其建立的无标记、高保真分析平台，也为深入探索物理微环境对细胞行为的影响开辟了新途径，在神经科学和再生医学领域具有重要应用前景。

---

## 13. 氯诺贝特通过破坏SNORA80B/YTHDC1驱动的M6A甲基化修饰以抑制食管鳞癌的胆固醇代谢和顺铂耐药性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41178567](https://pubmed.ncbi.nlm.nih.gov/41178567)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41178567
**DOI：** 10.1002/advs.202509574

### 第一部分 原文与翻译

**英文原标题：** Clinofibrate Disrupts the SNORA80B/YTHDC1-Driven M6A Modification to Suppress Cholesterol Metabolism and Cisplatin Resistance in ESCC.

**英文摘要原文：**
Esophageal squamous cell carcinoma (ESCC) progression is driven by androgen receptor (AR) signaling, while small nucleolar RNAs (snoRNAs), classically involved in ribosomal RNA processing, are increasingly recognized for non-classical roles in cancer. However, their function in ESCC remains unknown. This study investigates AR-regulated snoRNAs and their mechanistic contributions to ESCC pathogenesis. SNORA80B is identified as the most AR-responsive snoRNA with oncogenic activity by transcriptomic profiling. Beyond its classical role, SNORA80B stabilizes cholesterol metabolism transcripts via N⁶-methyladenosine (mA)-YTHDC1, driving cholesterol/DHT accumulation and lipid droplets (LDs) formation. A feedforward loop is observed wherein DHT-activated AR upregulates SNORA80B, which further enhances AR signaling through cholesterol metabolic reprogramming. Clinofibrate, identified as a SNORA80B inhibitor through high-throughput screening of FDA-approved drugs, disrupts this axis and demonstrates synergistic effects with cisplatin, overcoming resistance in ESCC. The study reveals a novel non-classical function of SNORA80B in ESCC, establishing it as a key effector of AR-driven metabolic reprogramming through m⁶A-dependent regulation. The repurposing of clinofibrate demonstrates the therapeutic potential of targeting snoRNA-mediated pathways, providing both mechanistic insights and a clinically translatable strategy for ESCC treatment. These findings redefine the functional scope of snoRNAs in cancer pathogenesis.

**中文摘要译文：**
食管鳞状细胞癌（ESCC）的进展由雄激素受体（AR）信号通路驱动，而经典参与核糖体RNA加工的小核仁RNA（snoRNA）在癌症中的非经典作用正日益受到关注。然而，其在ESCC中的功能仍然未知。本研究旨在探究受AR调控的snoRNA及其在ESCC发病机制中的作用。通过转录组分析，SNORA80B被鉴定为最具AR响应性且具有致癌活性的snoRNA。除了其经典作用外，SNORA80B通过N⁶-甲基腺嘌呤（m⁶A）-YTHDC1通路稳定胆固醇代谢相关转录本，从而驱动胆固醇/双氢睾酮（DHT）的积累和脂滴（LDs）的形成。研究观察到一个正反馈循环，即DHT激活的AR上调SNORA80B，而SNORA80B通过胆固醇代谢重编程进一步增强AR信号。通过对FDA批准药物的高通量筛选，发现氯诺贝特（Clinofibrate）是SNORA80B的抑制剂，它能破坏这一调控轴，并与顺铂产生协同效应，从而克服ESCC的耐药性。该研究揭示了SNORA80B在ESCC中的一种新的非经典功能，确立了其作为AR驱动的、通过m⁶A依赖性调控实现代谢重编程的关键效应因子。氯诺贝特的老药新用展示了靶向snoRNA介导通路的治疗潜力，为ESCC的治疗提供了机制性见解和临床转化策略。这些发现重新定义了snoRNA在癌症发病机制中的功能范围。

### 第二部分 AI 大师评价

本研究旨在揭示雄激素受体（AR）调控的小核仁RNA（snoRNA）在食管鳞癌（ESCC）中的作用机制。研究通过转录组学分析，首次发现SNORA80B作为关键致癌分子，能通过m6A甲基化依赖的方式调控胆固醇代谢，进而促进肿瘤进展和顺铂耐药。该研究的创新之处在于揭示了snoRNA的非经典功能，并筛选出老药氯诺贝特作为有效抑制剂，不仅深化了对ESCC代谢重编程的理解，也为治疗耐药性ESCC提供了极具潜力的临床转化策略。

---

## 14. 不同器官的姐妹疾病：一个关于锚定于阳性扫描结果的警戒性案例

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41178546](https://pubmed.ncbi.nlm.nih.gov/41178546)
**期刊：** Circulation
**PMID：** 41178546
**DOI：** 10.1161/CIRCULATIONAHA.125.076108

### 第一部分 原文与翻译

**英文原标题：** Twin Diseases in Different Organs: A Cautionary Tale of Anchoring on a Positive Scan.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本文很可能是一篇临床案例报告或评述，旨在警示临床医生一种常见的诊断陷阱——锚定偏见。文章通过一个“不同器官的姐妹疾病”的案例，深刻揭示了当医生过分依赖某一阳性扫描结果时，可能如何忽视或延迟对并存疾病的诊断。其核心价值在于临床教育，强调了在诊断过程中保持开放性思维、警惕认知偏见的重要性。尽管缺乏摘要，但仅从标题便可预见，该文对于提升临床医生的诊断思维和避免医疗差错具有重要的实践指导意义。

---

## 15. 解析过渡金属依赖性细胞死亡：机制、串扰及未来方向

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41178545](https://pubmed.ncbi.nlm.nih.gov/41178545)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41178545
**DOI：** 10.1002/advs.202501974

### 第一部分 原文与翻译

**英文原标题：** Navigating Transition Metal-Dependent Cell Death: Mechanisms, Crosstalk, and Future Directions.

**英文摘要原文：**
Regulated cell death is fundamental to cellular homeostasis, with metal-dependent pathways emerging as critical mechanisms influencing cell fate decisions. This comprehensive review examines the emerging landscape of metal-dependent regulated cell death pathways, focusing on ferroptosis, cuproptosis, and the hypothetical concept of "cobaltosis." Ferroptosis, characterized by iron-catalyzed lipid peroxidation and glutathione depletion, has emerged as a critical pathway in cancer, neurodegeneration, and ischemia-reperfusion injury. Cuproptosis, a recently defined copper-induced death mechanism, operates through direct binding of copper to lipoylated mitochondrial proteins, causing proteotoxic stress and metabolic collapse. Evidence for cobaltosis is critically evaluated as a potential distinct regulated cell death pathway, cobalt's known cellular impacts are examined, and a rigorous experimental framework is proposed for its investigation and validation as a distinct entity. This review comparatively analyzes the core mechanisms, highlighting the distinct roles of reactive oxygen species and mitochondria in each pathway. The intricate crosstalk and divergence among these death modalities are explored, introducing the concept of a "metal death code" that dictates the cellular fate in response to specific metal stresses. Furthermore, advanced technologies for detecting and dissecting these pathways are discussed, and their significant translational potential for treating diseases characterized by metal dyshomeostasis is considered, such as cancer and neurodegeneration.

**中文摘要译文：**
程序性细胞死亡是细胞稳态的基础，而金属依赖性通路正成为影响细胞命运决定的关键机制。这篇综述全面探讨了金属依赖性程序性细胞死亡通路的新兴领域，重点关注铁死亡、铜死亡以及“钴死亡”这一假说概念。铁死亡的特征是铁催化的脂质过氧化和谷胱甘肽耗竭，它已成为癌症、神经退行性疾病和缺血再灌注损伤中的一个关键通路。铜死亡是近期被定义的一种铜诱导的死亡机制，其通过铜与硫辛酰化的线粒体蛋白直接结合，引发蛋白毒性应激和代谢崩溃。文章审慎评估了将钴死亡作为一种潜在的、独特的程序性细胞死亡通路的证据，考察了钴已知的细胞效应，并为其作为独立实体的研究和验证提出了严谨的实验框架。本综述比较分析了这些死亡方式的核心机制，强调了活性氧和线粒体在每条通路中的不同作用。文章探讨了这些死亡模式之间复杂的串扰与分歧，并引入了“金属死亡密码”的概念，该密码决定了细胞在应对特定金属应激时的命运。此外，文章还讨论了用于检测和解析这些通路的先进技术，并展望了它们在治疗以金属稳态失调为特征的疾病（如癌症和神经退行性疾病）方面的巨大转化潜力。

### 第二部分 AI 大师评价

该综述系统性地梳理了金属依赖性细胞死亡这一前沿领域，其核心目的在于深入解析铁死亡、铜死亡及潜在的“钴死亡”等关键通路。文章通过比较分析阐明了各通路的核心机制、复杂的相互作用，并创新性地提出了“金属死亡密码”概念来解释细胞如何响应不同的金属应激。此项工作不仅为理解细胞死亡调控提供了新的理论框架，也为开发针对金属稳态失调相关疾病（如癌症和神经退行性疾病）的新型治疗策略指明了方向，具有重要的科研和临床转化价值。

---

## 16. 磁电纳米疗法在胰腺癌鼠模型中实现肿瘤完全消融并延长生存期

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41178530](https://pubmed.ncbi.nlm.nih.gov/41178530)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41178530
**DOI：** 10.1002/advs.202517228

### 第一部分 原文与翻译

**英文原标题：** Magnetoelectric Nanotherapy Achieves Complete Tumor Ablation and Prolonged Survival in Pancreatic Cancer Murine Models.

**英文摘要原文：**
Magnetoelectric nanoparticles (MENPs), when activated by a magnetic field, are shown to provide a minimally invasive, drug-free, theranostic approach to pancreatic ductal adenocarcinoma (PDAC) treatment. The magnetoelectric effect allows intravenously administered MENPs to be magnetically guided to PDAC xenograft tumors and remotely activated with a 7T-MRI field to induce targeted, electrode-free tumor ablation with real-time imaging feedback. A single MENP treatment achieved a threefold median reduction in tumor volume and complete tumor responses in 33.3% of mice at 300 and 600 µg doses (N = 17) and significantly longer mean overall survival as compared to the control cohorts (54.1 vs 28.8 days, χ = 40.14, p = 0.045), without evident toxicity in any imaged organ. In contrast, mice receiving subtherapeutic doses, non-activated MENPs, or saline controls showed no significant response. MRI T* relaxation time decreases closely correlated with tumor reduction (ρ = -0.73, p < 0.001), supporting MENPs as both a therapeutic and imaging biomarker. Mechanistically, MENPs preferentially target cancer cells via magnetic-field-driven electrostatic interactions specific to tumor cell membranes, in agreement with multiphysics numerical simulations. Flow cytometry confirmed that MENP activation primarily induces apoptosis, with minimal necrosis, and time-course studies showed a progressive apoptotic response over 3-hour post-treatment. The findings establish MENPs as a versatile, image-guided, theranostic platform with translational promise for minimally invasive oncology.

**中文摘要译文：**
磁电纳米颗粒（MENPs）在磁场激活下，被证实为胰腺导管腺癌（PDAC）的治疗提供了一种微创、无药物的诊疗一体化方法。磁电效应使得静脉注射的MENPs能够被磁力引导至PDAC异种移植肿瘤处，并通过7T-MRI场进行远程激活，以诱导靶向、无电极的肿瘤消融，并提供实时影像反馈。单次MENP治疗在300和600微克剂量下（N=17），实现了肿瘤体积中位数三倍的缩小，并在33.3%的小鼠中观察到完全的肿瘤缓解；与对照组相比，其平均总生存期显著延长（54.1天 vs 28.8天, χ = 40.14, p = 0.045），且在所有成像器官中未发现明显毒性。相比之下，接受亚治疗剂量、未激活的MENPs或生理盐水对照的小鼠则未显示出显著反应。MRI T2*弛豫时间的减少与肿瘤缩小密切相关（ρ = -0.73, p < 0.001），这支持MENPs可同时作为治疗和影像生物标志物。从机制上讲，与多物理场数值模拟结果一致，MENPs通过磁场驱动的、针对肿瘤细胞膜特异性的静电相互作用，优先靶向癌细胞。流式细胞术证实，MENP的激活主要诱导细胞凋亡，坏死极少，且时程研究显示治疗后3小时内细胞凋亡反应呈进行性增强。这些发现确立了MENPs作为一个多功能的、影像引导的诊疗一体化平台，在微创肿瘤学领域具有转化应用的潜力。

### 第二部分 AI 大师评价

本研究旨在探索一种新型磁电纳米颗粒（MENPs）疗法在胰腺癌治疗中的应用。研究通过外部磁场远程激活靶向肿瘤的MENPs，成功在小鼠模型中实现了无药物、微创的肿瘤消融，并显著延长了生存期。其关键创新在于将磁电效应应用于肿瘤治疗，构建了一个集靶向、治疗与实时影像监控于一体的诊疗平台，通过诱导细胞凋亡而非坏死来减少副作用。该技术为恶性实体瘤，特别是难治性胰腺癌，提供了一种极具转化潜力的物理治疗新策略。

---

## 17. 将肿瘤细胞原位工程化改造为自我维持的cDC1编程工厂以实现有效的癌症免疫治疗

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41178526](https://pubmed.ncbi.nlm.nih.gov/41178526)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41178526
**DOI：** 10.1002/advs.202508632

### 第一部分 原文与翻译

**英文原标题：** In Situ Engineering of Tumor Cells as Self-Sustaining cDC1 Programming Factories for Effective Cancer Immunotherapy.

**英文摘要原文：**
Conventional type 1 dendritic cells (cDC1s) play a crucial role in initiating and regulating antitumor immunity. However, the insufficient infiltration and dysfunctional state of these cells within the tumor microenvironment hinder antitumor immune response. A tumor-derived extracellular vesicle (EV), termed AS16-EL@MPLA/p-FX, is designed to engineer tumor cells into cDC1 programming factories. The EV lumen carries a plasmid encoding XCL1 and FLT3L. Leveraging the prolonged circulation time and homotypic targeting properties of tumor-derived EV, AS16-EL@MPLA/p-FX demonstrates enhanced tumor-selective accumulation and efficient cellular internalization. Following uptake, tumor cells are reprogrammed into in situ cytokine factories that continuously secrete XCL1 and FLT3L, which effectively recruit and differentiate cDC1s within the tumor microenvironment. Simultaneously, MPLA embedded in the EV membrane is released locally and activates the newly accumulated cDC1s through the TLR4 pathway. Furthermore, an AS16 peptide is tethered to the EV surface via a matrix metalloproteinase-2-cleavable linker. The enzymatic release of AS16 disrupts the VEGF-NRP1 interaction, preventing cDC1 exhaustion. The engineered EV, AS16-EL@MPLA/p-FX, exhibited remarkable tumor-targeting capabilities, promoting the recruitment, differentiation, and activation of cDC1s. This innovative approach not only significantly inhibited tumor growth but also triggered a robust immune memory response, safeguarding against tumor metastasis and recurrence.

**中文摘要译文：**
常规1型树突状细胞（cDC1s）在启动和调节抗肿瘤免疫中发挥着关键作用。然而，这些细胞在肿瘤微环境中的浸润不足和功能失调状态阻碍了抗肿瘤免疫应答。本研究设计了一种名为AS16-EL@MPLA/p-FX的肿瘤源性细胞外囊泡（EV），其旨在将肿瘤细胞改造为cDC1编程工厂。该EV的内腔携带一个编码XCL1和FLT3L的质粒。利用肿瘤源性EV的长循环时间和同型靶向特性，AS16-EL@MPLA/p-FX展现出增强的肿瘤选择性蓄积和高效的细胞内化能力。被摄取后，肿瘤细胞被重编程为原位细胞因子工厂，持续分泌XCL1和FLT3L，从而在肿瘤微环境中有效招募并分化cDC1s。同时，包埋在EV膜中的MPLA在局部释放，并通过TLR4通路激活新聚集的cDC1s。此外，一个AS16肽通过一个基质金属蛋白酶-2可裂解的连接子被束缚在EV表面。AS16的酶促释放会破坏VEGF-NRP1的相互作用，从而防止cDC1的耗竭。经过工程化改造的EV，即AS16-EL@MPLA/p-FX，表现出卓越的肿瘤靶向能力，促进了cDC1s的招募、分化和激活。这种创新方法不仅显著抑制了肿瘤生长，还触发了强大的免疫记忆反应，从而防止肿瘤的转移和复发。

### 第二部分 AI 大师评价

本研究旨在解决肿瘤微环境中cDC1细胞浸润不足与功能障碍的核心难题。研究团队设计了一种多功能的肿瘤源性细胞外囊泡，它能靶向并“策反”肿瘤细胞，使其转变为持续招募、分化并激活cDC1的“原位工厂”。该策略巧妙地集肿瘤靶向、细胞重编程、免疫激活及防止免疫耗竭于一体，不仅在抑制肿瘤生长、预防转移复发方面展现出强大效果，更代表了一种将“敌人”转化为“盟友”的创新性免疫治疗思路，具有重要的临床转化潜力。

---

## 18. 三阴性乳腺癌细胞通过白细胞介素-11反式信号转导抵抗自然杀伤细胞介导的杀伤作用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41178513](https://pubmed.ncbi.nlm.nih.gov/41178513)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41178513
**DOI：** 10.1002/advs.202515772

### 第一部分 原文与翻译

**英文原标题：** Triple-Negative Breast Cancer Cells Resist Natural Killer Cell-Mediated Killing Through Interleukin-11 Trans-Signaling.

**英文摘要原文：**
Natural killer (NK) cell-based therapies show great promise for treating triple-negative breast cancer (TNBC). However, in the tumor microenvironment, some TNBC cells develop resistance to NK cell-mediated killing and contribute to NK cell exhaustion. In this study, TNBC cell populations are isolated that can resist NK cell attacks and uncovered the underlying mechanisms. It is found that these resistant TNBC cells secrete high levels of interleukin-11 (IL-11). IL-11 acts through a process known as trans-signaling by forming complexes with the soluble IL-11 receptor (sIL-11R) and engaging the gp130 receptor on NK cells. This trans-signaling activates the JAK1/STAT1/3 pathway, leading to the upregulation of p21 and subsequent cell cycle arrest in NK cells. As a result, the proliferation and IFNγ production of NK cells are inhibited, enabling TNBC cells to resist NK cell-mediated killing. Disrupting IL-11 or sIL-11R in TNBC cells restores NK cell activity. Importantly, it is also found that IL-11 expression is elevated in human TNBC tissues and negatively correlated with the number of NK cells in the tumor microenvironment. These findings identify IL-11 trans-signaling as a novel mechanism of immune evasion in TNBC and suggest that targeting this pathway may enhance the effectiveness of NK cell-based therapies.

**中文摘要译文：**
基于自然杀伤（NK）细胞的疗法在治疗三阴性乳腺癌（TNBC）方面显示出巨大潜力。然而，在肿瘤微环境中，部分TNBC细胞对NK细胞介导的杀伤产生抵抗，并导致NK细胞耗竭。本研究分离出了能够抵抗NK细胞攻击的TNBC细胞群体，并揭示了其潜在机制。研究发现，这些耐药的TNBC细胞会分泌高水平的白细胞介素-11（IL-11）。IL-11通过一种称为反式信号转导的过程发挥作用，即与可溶性IL-11受体（sIL-11R）形成复合物，并与NK细胞上的gp130受体结合。这种反式信号转导激活了JAK1/STAT1/3通路，导致p21上调，并随后引起NK细胞的细胞周期停滞。结果，NK细胞的增殖和IFNγ的产生受到抑制，从而使TNBC细胞能够抵抗NK细胞介导的杀伤。在TNBC细胞中阻断IL-11或sIL-11R能够恢复NK细胞的活性。重要的是，研究还发现IL-11在人类TNBC组织中表达升高，并与肿瘤微环境中NK细胞的数量呈负相关。这些发现将IL-11反式信号转导确定为TNBC中一种新的免疫逃逸机制，并提示靶向该通路可能会增强基于NK细胞疗法的效果。

### 第二部分 AI 大师评价

本研究旨在揭示三阴性乳腺癌（TNBC）细胞抵抗自然杀伤（NK）细胞杀伤作用的新机制。研究团队通过分离耐药TNBC细胞，发现其高表达的白细胞介素-11（IL-11）通过反式信号转导通路抑制了NK细胞的功能。此项关键发现不仅深刻揭示了TNBC的一种新型免疫逃逸策略，更重要的是，它为临床治疗提供了潜在的新靶点，即通过抑制IL-11通路来增强NK细胞疗法对TNBC的疗效，具有重要的转化医学价值。

---

## 19. 通过仿生纳米酶系统差异化调控T淋巴细胞与癌细胞的线粒体代谢以增强放射免疫治疗

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41178512](https://pubmed.ncbi.nlm.nih.gov/41178512)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41178512
**DOI：** 10.1002/advs.202515097

### 第一部分 原文与翻译

**英文原标题：** Differentiated T Lymphocytes and Cancer Cell Mitochondrial Metabolism to Enhance Radioimmunotherapy by a Biomimetic Nanozyme System.

**英文摘要原文：**
Strategies to enhance the anti-tumor immune response through the regulation of cellular metabolism are under intensive investigation. Herein, a T cell membrane (TCM)-coated biomimetic magnesium carbonate (MgCO)/Fe-CD hybrid nanozyme system loaded with the Pyruvate kinase M2 (PKM2) activator TEPP-46 (TFMP) is developed, designed to simultaneously induce mitochondrial metabolic reprogramming in both T cells and tumor cells following radiotherapy (RT). The TCM coating enables TFMP to specifically target tumor tissues that highly express PD-L1, where it competitively binds to PD-L1 and thereby alleviates immune checkpoint-mediated T cell suppression. Upon X-ray irradiation, TFMP continuously catalyzes the conversion of radiotherapy-generated hydrogen peroxide into hydroxyl radicals, thereby sustaining reactive oxygen species production, which leads to mitochondrial damage and immunogenic cell death in tumor cells. Moreover, TFMP can neutralize the acidic tumor microenvironment, while the released Mg and TEPP-46 further augment T cell activation and mitochondrial function, thereby increasing the production of ATP and granzyme B, which effectively eliminate residual tumor cells. Experimental results demonstrate that the combination of TFMP and RT can significantly inhibit tumor progression and activate anti-tumor immunotherapy. This TFMP enhances the efficacy of breast cancer radioimmunotherapy, offering a foundation for developing more comprehensive therapeutic approaches of breast cancer to achieve clinical benefits.

**中文摘要译文：**
通过调控细胞代谢来增强抗肿瘤免疫应答的策略正受到广泛研究。在此，我们开发了一种负载丙酮酸激酶M2（PKM2）激活剂TEPP-46的T细胞膜（TCM）包被的仿生碳酸镁（MgCO）/Fe-CD混合纳米酶系统（TFMP），旨在放射治疗（RT）后同时诱导T细胞和肿瘤细胞的线粒体代谢重编程。TCM涂层使TFMP能够特异性靶向高表达PD-L1的肿瘤组织，在此处它与PD-L1竞争性结合，从而减轻免疫检查点介导的T细胞抑制。在X射线照射下，TFMP可持续催化放射治疗产生的过氧化氢转化为羟基自由基，从而维持活性氧的产生，这会导致肿瘤细胞的线粒体损伤和免疫原性细胞死亡。此外，TFMP可以中和酸性肿瘤微环境，而释放的镁离子和TEPP-46能进一步增强T细胞的活化和线粒体功能，从而增加ATP和颗粒酶B的产生，有效清除残留的肿瘤细胞。实验结果表明，TFMP与RT的联合应用能显著抑制肿瘤进展并激活抗肿瘤免疫治疗。该TFMP增强了乳腺癌放射免疫治疗的疗效，为开发更全面的乳腺癌治疗方法以实现临床获益奠定了基础。

### 第二部分 AI 大师评价

本研究旨在开发一种新型仿生纳米酶系统，以增强乳腺癌的放射免疫治疗效果。研究团队构建了一种T细胞膜包被的、负载PKM2激活剂的纳米酶（TFMP），该系统巧妙地结合了靶向递送、免疫检查点阻断、类芬顿反应增强放疗、肿瘤微环境调节以及对T细胞和癌细胞的双重线粒体代谢重编程等多重机制。关键发现表明，该策略不仅能精准杀伤肿瘤细胞，还能显著激活T细胞功能，从而有效抑制肿瘤生长。这项工作通过协同增强放疗与免疫治疗，为开发更高效的实体瘤联合治疗方案提供了富有前景的新思路和实验依据。

---

## 20. NUSAP1通过招募DAXX抑制HIF驱动的三阴性乳腺癌进展

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41178464](https://pubmed.ncbi.nlm.nih.gov/41178464)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41178464
**DOI：** 10.1002/advs.202513380

### 第一部分 原文与翻译

**英文原标题：** NUSAP1 Recruits DAXX to Suppress HIF-Driven Triple-Negative Breast Cancer Progression.

**英文摘要原文：**
Nucleolar and spindle-associated protein 1 (NUSAP1) is critical for cancer progression. However, its function in cancers is context-dependent, and emerging evidence indicates that NUSAP1 possesses tumor suppressor functions, although the underlying mechanisms remain uncharted. In this study, NUSAP1 depletion is found to significantly increases the proliferation, migration, and invasion of triple-negative breast cancer (TNBC) cells in vitro and promotes TNBC progression in vivo, suggesting that NUSAP1 is a tumor suppressor in TNBC. Mechanistically, NUSAP1 bridges HIFα and the transcriptional repressor death domain-associated protein (DAXX) through its microtubule-associated domain (MAD) to recruit the methyltransferase SETDB1, thereby attenuating HIF transcriptional activity and the expression of its target genes by depositing the H3K9me3 repressive mark on hypoxia response elements (HREs). Intriguingly, an engineered MAD of NUSAP1, designated as Tumor Suppressor-MAD (TS-MAD), is developed, which effectively abrogates HIF transcriptional activity by bridging the DAXX-HIF interaction, consequently inhibiting HIF-driven TNBC progression. Moreover, NUSAP1 is identified as a novel HIF-repressed gene in TNBC cells, and its expression level shows a negative correlation with clinical outcomes in TNBC patients. These findings establish an HIF-NUSAP1 double-negative feedback loop in TNBC and validate TS-MAD as a potential therapeutic strategy for HIF-driven cancer.

**中文摘要译文：**
核仁与纺锤体相关蛋白1（NUSAP1）对癌症进展至关重要。然而，其在癌症中的功能具有背景依赖性，且新出现的证据表明NUSAP1具有肿瘤抑制功能，但其潜在机制尚不明确。在本研究中，发现NUSAP1的耗竭在体外能显著增加三阴性乳腺癌（TNBC）细胞的增殖、迁移和侵袭，并在体内促进TNBC的进展，这表明NUSAP1在TNBC中扮演着肿瘤抑制因子的角色。从机制上讲，NUSAP1通过其微管相关结构域（MAD）桥接HIFα与转录抑制因子死亡域相关蛋白（DAXX），进而招募甲基转移酶SETDB1，通过在缺氧反应元件（HREs）上沉积H3K9me3抑制性标记，从而减弱HIF的转录活性及其靶基因的表达。有趣的是，研究人员开发了一种工程化的NUSAP1微管相关结构域（MAD），命名为肿瘤抑制-MAD（TS-MAD），它能通过桥接DAXX与HIF的相互作用，有效废除HIF的转录活性，从而抑制HIF驱动的TNBC进展。此外，研究还发现NUSAP1是TNBC细胞中一个新的受HIF抑制的基因，其表达水平与TNBC患者的临床预后呈负相关。这些发现揭示了TNBC中存在的HIF-NUSAP1双负反馈回路，并验证了TS-MAD作为一种针对HIF驱动型癌症的潜在治疗策略的有效性。

### 第二部分 AI 大师评价

本研究创新性地揭示了NUSAP1在三阴性乳腺癌（TNBC）中扮演着与传统认知相反的肿瘤抑制角色。研究通过精密的分子机制探索，阐明了NUSAP1通过桥接DAXX与HIFα，招募SETDB1来抑制HIF转录活性的全新表观遗传调控通路，并发现了一个HIF-NUSAP1双负反馈环路。更具转化价值的是，研究团队基于此机制设计的工程化蛋白结构域（TS-MAD）展现出抑制肿瘤进展的潜力，为HIF驱动的癌症提供了精准的潜在治疗新策略，具有重要的科研与临床应用前景。

---

## 21. 受金属硫蛋白启发的单原子纳米酶不对称杂原子掺杂策略用于多酶生物催化

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41178457](https://pubmed.ncbi.nlm.nih.gov/41178457)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41178457
**DOI：** 10.1002/advs.202517502

### 第一部分 原文与翻译

**英文原标题：** Metallothionein-Inspired Asymmetric Heteroatom Doping of Single-Atom Nanozymes for Multi-Enzyme Biocatalysis.

**英文摘要原文：**
Single-atom catalysts (SACs) exhibit enzyme-mimicking activity but are often limited by single-enzyme-like functions and modest catalytic efficiency. Here, a metallothionein-inspired heteroatom doping strategy is reported to construct asymmetric Fe single-atom catalysts (FeNS). Fe⁺ is coordinated with cysteine via strong mercaptide bond formation, followed by zeolitic imidazolate framework-8 (ZIF-8) biomineralization and pyrolysis. The FeNS catalyst displays markedly enhanced multi-enzyme activities-including NADH oxidase-, oxidase-, peroxidase-, and catalase-like activities-with 1.35-4.60-fold improvements compared to sulfur (S)-free analogues. This high multi-enzyme efficiency arises from i) atomically dispersed Fe from biomineralization; ii) the large surface area and pore volume retained from the original metal-organic framework, and iii) the S-doping achieved through the strong mercaptide coordination between Fe and S. The S doping not only tunes electronic structure of Fe single atom to reduce activation barriers and enhances substrate interaction, but also facilitates charge transfer. As a result, FeNS induces ≈90% tumor cell suppression within one day through reactive oxygen species generation and disruption of the NADH/NAD⁺ balance, highlighting its strong potential for cancer therapy. This work provides a bioinspired strategy for advancing SACs toward multifunctional biocatalysis and biomedical applications.

**中文摘要译文：**
单原子催化剂（SACs）具有模拟酶的活性，但通常受限于单一的类酶功能和中等的催化效率。本研究报道了一种受金属硫蛋白启发的杂原子掺杂策略，用于构建不对称的铁单原子催化剂（FeNS）。Fe⁺通过形成强的硫醇盐键与半胱氨酸配位，随后进行沸石咪唑酯骨架-8（ZIF-8）的生物矿化和热解。该FeNS催化剂表现出显著增强的多酶活性——包括类NADH氧化酶、类氧化酶、类过氧化物酶和类过氧化氢酶活性——与不含硫（S）的类似物相比，活性提高了1.35-4.60倍。这种高的多酶效率源于：i）生物矿化实现的原子级分散的铁；ii）保留了原始金属有机框架的大比表面积和孔体积；iii）通过铁与硫之间强的硫醇盐配位实现的硫掺杂。硫掺杂不仅调节了铁单原子的电子结构以降低活化能并增强底物相互作用，而且还促进了电荷转移。因此，FeNS通过产生活性氧和破坏NADH/NAD⁺平衡，在一天内诱导了约90%的肿瘤细胞抑制，凸显了其在癌症治疗中的巨大潜力。这项工作为推动单原子催化剂（SACs）向多功能生物催化和生物医学应用发展提供了一种生物启发策略。

### 第二部分 AI 大师评价

本研究受金属硫蛋白启发，巧妙地设计了一种不对称杂原子（硫）掺杂策略，成功构建了具有多种酶催化活性的铁单原子纳米酶（FeNS）。其核心创新在于通过生物矿化和硫醇盐键合，精确调控了单原子铁的电子结构，从而显著提升了其催化效率。研究结果表明，该纳米酶能通过产生活性氧和破坏代谢平衡来高效抑制肿瘤细胞，这不仅为开发多功能纳米酶提供了新思路，也展示了其在癌症催化治疗领域的巨大应用潜力。

---

## 22. 更正：伴有节段性重复的肿瘤抑制基因易于发生体细胞缺失和结构变异

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41178360](https://pubmed.ncbi.nlm.nih.gov/41178360)
**期刊：** Cancer research
**PMID：** 41178360
**DOI：** 10.1158/0008-5472.CAN-25-3745

### 第一部分 原文与翻译

**英文原标题：** Correction: Tumor Suppressor Genes with Segmental Duplications Are Prone to Somatic Deletions and Structural Variations.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

此文献是一篇更正声明，针对一项关于肿瘤抑制基因易感性的重要研究。原始研究可能揭示了位于节段性重复区域的肿瘤抑制基因更容易发生体细胞缺失和结构变异，这为理解癌症中的基因组不稳定性提供了新的视角。该更正对于维护相关研究发现的科学准确性至关重要，并强调了基因组结构在肿瘤发生发展中的关键作用。虽然本身不提供新的实验数据，但它确保了这一领域知识基础的严谨性。

---

## 23. 编者按：MDM2/MDMX-p53拮抗剂PM2对野生型p53肿瘤具有放射增敏作用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41178359](https://pubmed.ncbi.nlm.nih.gov/41178359)
**期刊：** Cancer research
**PMID：** 41178359
**DOI：** 10.1158/0008-5472.CAN-25-4015

### 第一部分 原文与翻译

**英文原标题：** Editor's Note: The MDM2/MDMX-p53 Antagonist PM2 Radiosensitizes Wild-Type p53 Tumors.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献为一篇“编者按”，并非原创性研究论文。其核心目的在于对一篇关于MDM2/MDMX-p53拮抗剂PM2对野生型p53肿瘤放射增敏作用的研究进行说明或更正。由于缺乏摘要信息，无法评估其具体研究方法与关键发现。此类编者按对于维护学术记录的准确性和完整性至关重要，但其本身不提供新的实验证据，读者需结合其引用的原始研究进行全面解读。

---

## 24. 发掘并利用前列腺癌中与雄激素受体协同的代谢脆弱性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41178358](https://pubmed.ncbi.nlm.nih.gov/41178358)
**期刊：** Cancer research
**PMID：** 41178358
**DOI：** 10.1158/0008-5472.CAN-25-3234

### 第一部分 原文与翻译

**英文原标题：** Exploiting AR-Synergistic Metabolic Vulnerabilities in Prostate Cancer.

**英文摘要原文：**
Resistance to androgen deprivation therapy remains a major clinical challenge in prostate cancer, necessitating alternative therapeutic strategies. The androgen receptor (AR) plays a central role in driving resistance through mechanisms including enhanced AR signaling, DNA repair, and autophagy. In this issue of Cancer Research, Cordova and colleagues identify a metabolic vulnerability in AR protein synthesis, showing that alternate-day fasting (ADF) impairs AR translation by inducing ribosome collisions on AR mRNA. This stress response activates kinases such as p38 MAPK and selectively reduces AR protein levels, independent of transcription or protein stability. Notably, ADF enhances the efficacy of enzalutamide across multiple prostate cancer models. Unlike conventional AR-targeting approaches, ADF reveals a posttranscriptional dependency of AR expression under nutrient stress while sparing most other proteins. These findings highlight a novel translational vulnerability in prostate cancer and support combining dietary interventions with AR-targeted therapies to overcome resistance and improve patient outcomes. See related article by Cordova et al., p. 4182.

**中文摘要译文：**
对雄激素剥夺疗法的耐药性仍然是前列腺癌治疗中的一个主要临床挑战，因此需要替代性的治疗策略。雄激素受体（AR）通过增强AR信号传导、DNA修复和自噬等机制，在驱动耐药性方面发挥着核心作用。在本期《癌症研究》中，Cordova及其同事发现了一个AR蛋白合成中的代谢脆弱性，他们证明隔日禁食（ADF）通过诱导AR mRNA上的核糖体碰撞来损害AR的翻译过程。这种应激反应激活了p38 MAPK等激酶，并选择性地降低了AR蛋白水平，这一过程独立于转录或蛋白稳定性。值得注意的是，在多种前列腺癌模型中，隔日禁食增强了恩杂鲁胺的疗效。与传统的AR靶向方法不同，隔日禁食揭示了在营养应激下AR表达的转录后依赖性，同时对大多数其他蛋白质没有影响。这些发现凸显了前列腺癌中一个新的翻译层面的脆弱性，并支持将饮食干预与AR靶向疗法相结合，以克服耐药性并改善患者预后。详见Cordova等人的相关文章，第4182页。

### 第二部分 AI 大师评价

本研究旨在解决前列腺癌对雄激素剥夺疗法的耐药性问题。研究者创新性地采用隔日禁食（ADF）作为干预手段，发现ADF能通过干扰AR mRNA的翻译过程，选择性地降低雄激素受体（AR）蛋白水平，从而增强了靶向药物恩杂鲁胺的疗效。此发现揭示了AR表达在营养应激下的一个全新翻译层面的脆弱性，为联合饮食干预与AR靶向治疗以克服耐药性提供了新的理论依据和临床转化潜力。

---

## 25. 胚系突变作为癌症药物靶点

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41178351](https://pubmed.ncbi.nlm.nih.gov/41178351)
**期刊：** Cancer discovery
**PMID：** 41178351
**DOI：** 10.1158/2159-8290.CD-24-1241

### 第一部分 原文与翻译

**英文原标题：** Germline Mutations as Cancer Drug Targets.

**英文摘要原文：**
UNLABELLED: Hereditary cancer syndromes are associated with causative pathogenic variants and clinical pathologies. Therapeutic advances have provided proof-of-concept for the actionability of the germline, whereas epidemiologic studies have identified pathogenic germline variants across tumor types regardless of hereditary syndromes. Drug development advances in synthetic lethal approaches, immunotherapeutics, cancer vaccines, and other strategies have led to regulatory approval of multiple agents, supporting the incorporation of universal germline testing. We review the current landscape of germline mutations as cancer drug targets, compare available clinical diagnostics, discuss the development of promising antitumor agents, and envision the future of universal germline testing in cancer medicine.

SIGNIFICANCE: Recent studies have led to the development of novel therapeutic strategies that are redefining germline BRCA1/2, MSH2, VHL, and other alterations as therapeutically actionable. The current cost-effectiveness of high-throughput germline testing has now made it feasible to consider universal germline testing for all patients with cancer, which will ease access to an increasingly large and effective therapeutic portfolio.

**中文摘要译文：**
无标签：遗传性癌症综合征与致病性基因变异及临床病理学相关。治疗学的进步为胚系突变的可操作性（靶向治疗）提供了概念验证，而流行病学研究则揭示了在各种肿瘤类型中均存在致病性胚系变异，这与是否存在遗传综合征无关。在合成致死、免疫疗法、癌症疫苗及其他策略方面的药物研发进展，已促使多种药物获得监管批准，从而支持将普适性胚系检测纳入临床实践。本文综述了将胚系突变作为癌症药物靶点的研究现状，比较了现有的临床诊断方法，讨论了有前景的抗肿瘤药物的开发，并展望了普适性胚系检测在肿瘤医学领域的未来。

重要性：近期的研究推动了新型治疗策略的发展，这些策略正在重新定义胚系BRCA1/2、MSH2、VHL及其他基因改变，将其视为可治疗的靶点。当前，高通量胚系检测的成本效益已使得对所有癌症患者进行普适性胚系检测变得可行，这将使患者更容易获得日益增多且有效的治疗选择。

### 第二部分 AI 大师评价

本文是一篇前瞻性的综述，系统性地阐述了将胚系突变作为癌症治疗靶点的最新进展。文章总结了合成致死和免疫疗法等领域的突破如何使BRCA1/2等传统遗传性基因突变转变为可操作的药物靶点，并强调了高通量测序的成本效益。其核心价值在于高屋建瓴地倡导对所有癌症患者进行普适性胚系检测，这一观点对推动精准肿瘤学的临床实践、扩大靶向治疗的获益人群具有重大的指导意义和临床价值。

---

## 26. GLP-1受体激动剂会削弱肥胖与癌症之间的关联吗？

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41178350](https://pubmed.ncbi.nlm.nih.gov/41178350)
**期刊：** Cancer discovery
**PMID：** 41178350
**DOI：** 10.1158/2159-8290.CD-25-0991

### 第一部分 原文与翻译

**英文原标题：** Will GLP-1 Agonists Weaken the Links between Obesity and Cancer?

**英文摘要原文：**
Glucagon-like peptide 1 receptor agonists hold great promise to reverse some cancer risk in people living with obesity, and emerging clinical trials support this so far. However, some preclinical work and caveats from human studies highlight that more work is needed to understand the mechanisms and full potential of antiobesity medicines in cancer.

**中文摘要译文：**
胰高血糖素样肽-1受体激动剂在逆转肥胖人群的某些癌症风险方面显示出巨大潜力，目前新出现的临床试验也支持了这一点。然而，一些临床前研究和来自人体研究的警示表明，仍需开展更多工作来理解抗肥胖药物在癌症领域的具体作用机制和全部潜力。

### 第二部分 AI 大师评价

该文献精准地抓住了当前医学研究的热点，探讨了GLP-1受体激动剂在打破肥胖与癌症之间关联中的潜在作用。文章综合评述了现有临床试验的积极证据与临床前研究的警示信号，提出了一个平衡的视角。此文的核心价值在于前瞻性地指出了抗肥胖药物在肿瘤预防和治疗领域的重要前景，同时也强调了深入研究其作用机制的必要性，为未来的研究方向提供了重要参考。

---

## 27. 人造甜味剂在癌症免疫治疗中的苦涩余味

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41178349](https://pubmed.ncbi.nlm.nih.gov/41178349)
**期刊：** Cancer discovery
**PMID：** 41178349
**DOI：** 10.1158/2159-8290.CD-25-1431

### 第一部分 原文与翻译

**英文原标题：** The Bitter Aftertaste of Artificial Sweeteners in Cancer Immunotherapy.

**英文摘要原文：**
Morder, Nguyen, Wilfahrt, and colleagues report that nonnutritive sweeteners impair the efficacy of anti-PD-1 therapy through mechanisms that involve regulation of microbiota and metabolites. Their findings underscore the clinical relevance of long-term lifestyle interventions, such as limiting daily intake of nonnutritive sweeteners, across multiple cancer types. See related article by Morder et al., p. 2278.

**中文摘要译文：**
Morder、Nguyen、Wilfahrt及其同事报告称，非营养性甜味剂通过涉及调节微生物群和代谢物的机制，损害了抗PD-1疗法的疗效。他们的研究结果强调了长期生活方式干预（例如限制非营养性甜味剂的每日摄入量）在多种癌症类型中的临床相关性。详见Morder等人的相关文章，第2278页。

### 第二部分 AI 大师评价

本文是一篇针对Morder等人研究的评论性文章，重点阐述了其核心发现。该研究揭示了非营养性甜味剂（人造甜味剂）如何通过调节肠道微生物群及其代谢产物，从而削弱抗PD-1免疫治疗的疗效。这一发现具有重要的临床指导意义，首次将常见的饮食因素与前沿的癌症免疫治疗效果直接关联，提示在治疗过程中进行饮食干预（如限制人造甜味剂摄入）可能成为改善患者预后的新策略。

---

## 28. 监测临床试验多样性趋势：持续的努力与进展

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41178348](https://pubmed.ncbi.nlm.nih.gov/41178348)
**期刊：** Cancer discovery
**PMID：** 41178348
**DOI：** 10.1158/2159-8290.CD-25-1432

### 第一部分 原文与翻译

**英文原标题：** Monitoring Trends in Clinical Trial Diversity: Ongoing Efforts and Progress.

**英文摘要原文：**
This spotlight summarizes key points from a new report that examined trends in the diversity of patients enrolled in NCI-sponsored early-phase clinical trials and identifies areas that should be examined as part of efforts to monitor recruitment and retention outcomes in ongoing and future cancer research studies. See related article by Farooq et al., p. 2251.

**中文摘要译文：**
本篇“聚光灯”文章总结了一份新报告的要点，该报告审查了美国国家癌症研究所（NCI）赞助的早期临床试验中入组患者多样性的趋势，并指出了在监测当前及未来癌症研究中招募和保留结局的工作中应予审视的领域。请参见Farooq等人的相关文章，第2251页。

### 第二部分 AI 大师评价

本文作为一篇“聚光灯”评论，聚焦于临床试验患者多样性的关键议题。它通过概述一份关于NCI早期临床试验入组趋势的报告，强调了持续监测受试者招募与保留的重要性。该文的核心价值在于，它不仅指出了当前研究在多样性方面的进展，更前瞻性地为未来研究确定了需要重点审视的领域，对推动癌症研究的公平性和普适性具有重要指导意义。

---

## 29. 从创新到影响：共同推进癌症研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41178347](https://pubmed.ncbi.nlm.nih.gov/41178347)
**期刊：** Cancer discovery
**PMID：** 41178347
**DOI：** 10.1158/2159-8290.CD-25-1637

### 第一部分 原文与翻译

**英文原标题：** From Innovation to Impact: Advancing Cancer Research Together.

**英文摘要原文：**
Cancer research has entered a transformative era, marked by rapid advances in immunotherapy, early detection, precision oncology, and artificial intelligence that are reshaping prevention, treatment, and survivorship. To sustain momentum, the global cancer community must unite around investment, collaboration, and equity to ensure every patient benefits from these breakthroughs.

**中文摘要译文：**
癌症研究已进入一个变革性时代，其标志是免疫疗法、早期检测、精准肿瘤学和人工智能领域的飞速发展，这些进步正在重塑癌症的预防、治疗和患者生存状况。为保持这一发展势头，全球癌症研究界必须在投资、协作和公平性方面团结一致，以确保每位患者都能从这些突破性进展中受益。

### 第二部分 AI 大师评价

该文献高屋建瓴地概括了癌症研究领域的现状与未来方向。文章并未呈现一项具体的研究，而是一篇具有纲领性的述评，明确指出了免疫疗法、精准肿瘤学及人工智能等前沿技术带来的变革性机遇。其核心价值在于倡导全球合作、增加投入并确保成果公平转化，旨在推动前沿科技创新切实转化为能惠及每一位患者的临床成果，深刻揭示了从“创新”到“影响”的实现路径。

---

## 30. 采用肿瘤信息引导的个性化ctDNA检测方法与可切除结直肠癌复发的关联：一项前瞻性观察研究的结果

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41177967](https://pubmed.ncbi.nlm.nih.gov/41177967)
**期刊：** Annals of surgery
**PMID：** 41177967
**DOI：** 10.1097/SLA.0000000000006971

### 第一部分 原文与翻译

**英文原标题：** Association of Recurrence with a Tumor-informed Personalized ctDNA Detection Approach in Resectable Colorectal Cancer: Results of a Prospective Observational Study.

**英文摘要原文：**
OBJECTIVE: Primary objective was to evaluate the association between post-surgical MRD detected by a tumor-informed personalized panel (brPROPHET) and CRC recurrence, Secondary objectives were to determine the optimal timepoint for MRD assessment, and compare the performance of different MRD detection methods, including brPROPHET, a tumor-informed fixed panel (TIFP) and a tumor-naïve fixed panel (TNFP).

SUMMARY OF BACKGROUND DATA: Circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) has emerged as a pivotal marker in colorectal cancer (CRC), but optimal detection timing and methods remain unclear.

METHODS: This study included patients with resectable stage I-IV CRC. Tumor tissues were obtained at surgery, and blood samples were collected preoperatively, on post-surgical days 7 and 30 (D7/D30), and every 3-6 months. MRD was assessed using the above three methods.

RESULTS: A total of 214 patients were included in the analysis, with imaging follow-up available for 196 patients (median follow-up: 18.2 months), among whom 24 (12.2%) experienced recurrence. MRD positivity at D7/D30 associated with significantly reduced disease-free survival (DFS). Longitudinal ctDNA-MRD positivity and MTM levels >0.01/mL were also associated with recurrence. Adjuvant chemotherapy was associated with better DFS in patients with positive MRD at D7 (HR=0.26, 95% CI 0.07-0.98, P=0.03) instead of those with negative MRD at D7. Among the 168 patients assessed with all three methods, the brPROPHET assay demonstrated better association of DFS at D7.

CONCLUSIONS: ctDNA-based MRD detected by brPROPHET associates with recurrence in CRC. Day 7 is an effective alternative landmark to Day 30 for MRD assessment and brPROPHET outperforms TIFP and TNFP in the association of DFS. ClinicalTrials.gov number: NCT06143644.

**中文摘要译文：**
目的：主要目标是评估通过肿瘤信息引导的个性化基因panel (brPROPHET) 检测的术后微小残留病灶 (MRD) 与结直肠癌 (CRC) 复发之间的关联。次要目标是确定 MRD 评估的最佳时间点，并比较不同 MRD 检测方法的性能，包括 brPROPHET、肿瘤信息引导的固定基因panel (TIFP) 和肿瘤原生固定基因panel (TNFP)。

背景资料概述：基于循环肿瘤DNA (ctDNA) 的分子残留病 (MRD) 已成为结直肠癌 (CRC) 的一个关键标志物，但其最佳检测时机和方法仍不明确。

方法：本研究纳入了可切除的 I-IV 期 CRC 患者。肿瘤组织在手术时获取，血液样本分别在术前、术后第7天和第30天 (D7/D30) 以及之后每3-6个月采集一次。使用上述三种方法评估 MRD。

结果：共有214名患者被纳入分析，其中196名患者有影像学随访数据（中位随访时间：18.2个月），当中24名 (12.2%) 经历了复发。D7/D30时MRD阳性与显著缩短的无病生存期 (DFS) 相关。纵向的ctDNA-MRD阳性以及MTM水平 >0.01/mL也与复发相关。在D7时MRD阳性的患者中，辅助化疗与更好的DFS相关 (HR=0.26, 95% CI 0.07-0.98, P=0.03)，而在D7时MRD阴性的患者中则无此关联。在接受所有三种方法评估的168名患者中，brPROPHET检测在D7时显示出与DFS更好的关联性。

结论：通过 brPROPHET 检测的基于 ctDNA 的 MRD 与 CRC 的复发相关。术后第7天是替代第30天进行 MRD 评估的有效时间点，并且在与 DFS 的关联性方面，brPROPHET 优于 TIFP 和 TNFP。ClinicalTrials.gov 注册号：NCT06143644。

### 第二部分 AI 大师评价

本研究通过一项前瞻性观察性研究，旨在评估一种名为brPROPHET的肿瘤信息引导个性化ctDNA检测方法在预测可切除结直肠癌（CRC）术后复发中的价值，并探索了最佳检测时机与方法。其核心发现证实，术后第7天通过brPROPHET检测到的分子残留病（MRD）阳性与患者较差的无病生存期显著相关，且该个性化方法在预测性能上优于固定的基因panel。这项研究的临床价值在于，它为术后CRC患者的风险分层和辅助治疗决策提供了更早（术后第7天）且更精准的生物标志物，推动了ctDNA在肿瘤精准监控领域的应用。

---

## 31. 癌症研究中区间删失数据的实用性综述与统计分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41177843](https://pubmed.ncbi.nlm.nih.gov/41177843)
**期刊：** Cancer communications (London, England)
**PMID：** 41177843
**DOI：** 10.1002/cac2.70073

### 第一部分 原文与翻译

**英文原标题：** A practical overview and statistical analysis of interval-censored data in cancer.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献从标题来看是一篇方法学综述，旨在为癌症研究领域的研究者提供关于“区间删失数据”的实用性概述和统计分析指导。文章的核心价值在于系统性地梳理了处理此类特殊数据（例如，肿瘤复发仅能确定在两次随访之间发生）的统计方法，这对于提高临床研究设计的严谨性和生存分析结果的准确性至关重要。虽然缺乏摘要限制了对其深度的具体判断，但该文对于需要处理非精确事件发生时间数据的临床医生和统计学家具有很高的实践指导意义。

---

## 32. 培养皿中重现体内肿瘤内异质性：可扩展的胚胎性脑肿瘤前脑类器官模型用于高通量个性化药物发现。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41177766](https://pubmed.ncbi.nlm.nih.gov/41177766)
**期刊：** Cancer communications (London, England)
**PMID：** 41177766
**DOI：** 10.1002/cac2.70074

### 第一部分 原文与翻译

**英文原标题：** In vivo intratumoral heterogeneity in a dish: scalable forebrain organoid models of embryonal brain tumors for high-throughput personalized drug discovery.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本研究的核心目标是开发一种新型的体外模型，以用于胚胎性脑肿瘤的个性化药物筛选。该研究通过构建可扩展的前脑类器官模型，成功在培养皿中再现了肿瘤内部的细胞异质性，这是传统二维细胞系培养难以实现的。这项技术的创新性在于，它为高通量筛选针对特定患者肿瘤的有效药物提供了一个更接近体内真实情况的平台，极大地推动了儿童脑肿瘤精准治疗的发展。尽管缺乏摘要信息，但仅从标题来看，该模型在临床前研究和新药研发中具有巨大的应用潜力。

---

## 33. 前列腺癌的药物靶点：聚焦于KLK2介导的破坏作用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40924642](https://pubmed.ncbi.nlm.nih.gov/40924642)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 40924642
**DOI：** 10.1158/1078-0432.CCR-25-2546

### 第一部分 原文与翻译

**英文原标题：** Drug Targets in Prostate Cancer: An Appetite for KLK2-Mediated Destruction.

**英文摘要原文：**
Human kallikrein (KLK) 2 is a prostate cancer tissue-specific protein that is regulated by androgen receptor signaling. KLK2 was not previously recognized as a therapeutic target as it was shown to be a secreted serine protease with no evidence for localization to the cell surface. It has now been demonstrated that KLK2 is expressed on the cell surface and is targetable by various methodologies. See related article by Shen et al., p. 4543.

**中文摘要译文：**
人激肽释放酶相关肽酶2（KLK2）是一种受雄激素受体信号通路调控的前列腺癌组织特异性蛋白。由于KLK2被证实为一种分泌型丝氨酸蛋白酶，且无证据表明其定位于细胞表面，因此以往未被认为是一个治疗靶点。现已证明，KLK2在细胞表面表达，并可通过多种方法进行靶向。详见Shen等人发表的相关文章，第4543页。

### 第二部分 AI 大师评价

本文献作为一篇前瞻性评论，精准地提炼了一项关于前列腺癌潜在新靶点KLK2的突破性发现。其核心价值在于指出了一个关键的认知转变：过去被普遍认为是分泌蛋白的KLK2，现被证实也稳定表达于癌细胞表面。这一发现颠覆了传统观点，将KLK2从一个单纯的生物标志物提升为可直接干预的治疗靶点，为开发抗体药物偶联物（ADC）、CAR-T等精准疗法开辟了全新路径，对晚期或难治性前列腺癌的治疗策略具有重大的启示意义和临床转化潜力。

---

## 34. 旨在缩小高血压管理差距的政策议程。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40900057](https://pubmed.ncbi.nlm.nih.gov/40900057)
**期刊：** Journal of the American College of Cardiology
**PMID：** 40900057
**DOI：** 10.1016/j.jacc.2025.08.011

### 第一部分 原文与翻译

**英文原标题：** Policy Agenda to Close the Hypertension Gap.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

根据标题判断，本文可能是一篇政策声明或专家共识，而非原创性研究。其核心目的在于提出一套旨在缩小高血压在诊断、治疗和控制方面差距的政策议程。该文的价值在于从宏观层面为政府、医疗机构及公共卫生组织提供了解决高血压管理不善问题的策略框架，对推动相关卫生政策的制定与实施、促进健康公平具有重要的指导意义和潜在影响。

---

## 35. ErbB2信号增强是雄激素信号抑制的一种早期适应性反应，并持续存在于去势抵抗性前列腺癌中

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40795068](https://pubmed.ncbi.nlm.nih.gov/40795068)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 40795068
**DOI：** 10.1158/1078-0432.CCR-22-3683

### 第一部分 原文与翻译

**英文原标题：** Increased ErbB2 Signaling Is an Early Adaptation to Androgen Signaling Inhibition and Persists in Castration-Resistant Prostate Cancer.

**英文摘要原文：**
PURPOSE: ErbB2 activity is increased in a subset of prostate cancer, but the gene is rarely amplified. This study sought to identify mechanisms driving increased ErbB2 activity and their role in progression to castration-resistant prostate cancer (CRPC).

EXPERIMENTAL DESIGN: ErbB2 signaling was interrogated with a combination of immunohistochemistry, reverse-phase protein array, and RNA sequencing in cell lines, xenografts, and clinical tumors at various stages of castration resistance. Sensitivity to ErbB2 inhibitors was tested in vitro and in vivo.

RESULTS: ErbB2 activation, identified by IHC with an antibody against phosphorylated ErbB2, was present in ∼26% of residual tumors in radical prostatectomies after neoadjuvant androgen signaling inhibition (ASI) and in advanced CRPC. The ErbB3/ErbB2-activating ligand NRG1 was found by IHC in ∼75% of neoadjuvant-treated tumors. NRG1 mRNA was rapidly increased by ASI in prostate cancer cells and xenografts and was increased in post-ASI data sets. Overexpression of an active ERBB2 splice variant (d16ERBB2) was also increased rapidly after ASI in prostate cancer cells and was found in a subset of CRPC. ErbB2 signaling in all models remained sensitive to the covalent ErbB2 inhibitor neratinib, which enhanced responses to castration and suppressed the growth of castration-resistant xenografts with ErbB2 activation.

CONCLUSIONS: Increased ErbB2 signaling is a rapid adaptation to ASI and contributes to castration resistance. Increases in NRG1 and d16ERBB2 contribute to increased ErbB2 signaling. Potent ErbB2 antagonists may enhance responses to ASI in castration-sensitive prostate cancer, and ErbB2 phosphorylation may be a biomarker for tumors that will respond in CRPC.

**中文摘要译文：**
目的：在一部分前列腺癌中，ErbB2活性有所增强，但其基因却很少发生扩增。本研究旨在探究导致ErbB2活性增强的机制及其在向去势抵抗性前列腺癌（CRPC）进展过程中的作用。

实验设计：本研究结合免疫组织化学、反相蛋白质芯片和RNA测序技术，对处于不同去势抵抗阶段的细胞系、异种移植物和临床肿瘤中的ErbB2信号通路进行了研究。同时，在体外和体内测试了肿瘤对ErbB2抑制剂的敏感性。

结果：通过使用磷酸化ErbB2抗体进行免疫组化检测发现，在新辅助雄激素信号抑制（ASI）治疗后的根治性前列腺切除术残留肿瘤中，约26%的病例以及晚期CRPC中均存在ErbB2激活。在约75%的新辅助治疗肿瘤中，通过免疫组化检测到了ErbB3/ErbB2的激活配体NRG1。在前列腺癌细胞和异种移植物中，ASI能迅速上调NRG1 mRNA的表达，并且在ASI治疗后的数据集中也观察到其表达增加。此外，一种活性的ERBB2剪接变体（d16ERBB2）的过表达在ASI处理后的前列腺癌细胞中也迅速增加，并在一部分CRPC中被发现。在所有模型中，ErbB2信号通路对共价ErbB2抑制剂奈拉替尼保持敏感；该药物增强了对去势治疗的反应，并抑制了存在ErbB2激活的去势抵抗性异种移植物的生长。

结论：ErbB2信号增强是机体对ASI的一种快速适应性反应，并促进了去势抵抗的发生。NRG1和d16ERBB2的增加是导致ErbB2信号增强的原因。强效的ErbB2拮抗剂可能增强去势敏感性前列腺癌对ASI的反应，而ErbB2的磷酸化水平可能成为预测CRPC肿瘤是否会对该类药物产生应答的生物标志物。

### 第二部分 AI 大师评价

该研究系统阐明了ErbB2信号通路在前列腺癌对雄激素信号抑制（ASI）产生适应性抵抗中的关键作用。研究创新性地揭示，这种抵抗并非源于传统的基因扩增，而是通过上调配体NRG1和一种活性剪接变体d16ERBB2来快速激活ErbB2信号。该研究最重要的发现是，这种适应性激活的通路对ErbB2抑制剂（如奈拉替尼）仍然敏感，从而为联合治疗提供了强有力的临床前证据。这项工作具有显著的转化价值，不仅提出了一种克服治疗抵抗的新策略，还指出了磷酸化ErbB2可作为筛选获益人群的潜在生物标志物。

---

## 36. PT-112（一种新型诱导免疫原性细胞死亡的小分子药物）治疗复发或难治性多发性骨髓瘤的I期临床研究及体内研究发现

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40795066](https://pubmed.ncbi.nlm.nih.gov/40795066)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 40795066
**DOI：** 10.1158/1078-0432.CCR-24-2574

### 第一部分 原文与翻译

**英文原标题：** A Phase I Clinical Study and In Vivo Findings with PT-112, a Novel Immunogenic Cell Death-Inducing Small Molecule, in Relapsed or Refractory Multiple Myeloma.

**英文摘要原文：**
PURPOSE: R,R-1,2 cyclohexanediamine-pyrophosphato-platinum(II) (PT-112) is a novel immunogenic cell death-inducing small molecule under phase II development in several cancer types. It inhibits ribosome biogenesis and causes organelle stresses, leading to selective immunogenic cell death in cancer cells. The possibility of PT-112's pyrophosphate moiety driving high drug concentrations to bone sites of disease has led to an interest in PT-112's use in multiple myeloma. In this study, we present findings from phase I and in vivo studies for PT-112 in relapsed or refractory multiple myeloma.

EXPERIMENTAL DESIGN: PT-112 biodistribution was analyzed in mice via laser ablation inductively coupled plasma mass spectrometry. The activity of PT-112 was assessed in de novo and transplantable Tg(Igkv3-5*-MYC)#Plbe (Vk*MYC) multiple myeloma mouse models as monotherapy or combination therapies. M-spike levels and survival were measured. A phase I dose escalation study of PT-112 monotherapy was conducted using a 3 + 3 design in patients with heavily pretreated relapsed or refractory multiple myeloma with exhausted available therapies.

RESULTS: In vivo biodistribution imaging revealed high concentrations in the bone, kidney, lung, skin, and liver. PT-112 was active in Vk*MYC multiple myeloma mouse models, both alone and in combination. Phase I data showed that PT-112 monotherapy was safe and well-tolerated, establishing a recommended phase II dose of 360 mg/m2 on days 1, 8, and 15 of a 28-day cycle. Confirmed responses and other signals of activity were observed.

CONCLUSIONS: These results suggest a lack of cross-resistance with the standard of care and support the translational value of the Vk*MYC model system. Further clinical investigation of PT-112 is warranted in multiple myeloma.

**中文摘要译文：**
目的：R,R-1,2-环己二胺-焦磷酸铂(II)（PT-112）是一种新型诱导免疫原性细胞死亡的小分子药物，正在多种癌症类型中进行II期开发。该药物通过抑制核糖体生物合成并引发细胞器应激，选择性地诱导癌细胞发生免疫原性细胞死亡。PT-112的焦磷酸盐部分可能使其在骨骼病灶部位富集，这引发了其在多发性骨髓瘤治疗中应用的研究兴趣。本研究旨在报告PT-112在复发或难治性多发性骨髓瘤中的I期临床研究及体内研究结果。

实验设计：通过激光烧蚀-电感耦合等离子体质谱法分析了PT-112在小鼠体内的生物分布。在原发及可移植的Tg(Igkv3-5*-MYC)#Plbe (Vk*MYC)多发性骨髓瘤小鼠模型中，评估了PT-112单药或联合治疗的活性。测量了M蛋白水平和生存期。采用“3+3”设计，在已用尽现有疗法的经多线治疗的复发或难治性多发性骨髓瘤患者中，开展了一项PT-112单药治疗的I期剂量递增研究。

结果：体内生物分布成像显示，药物在骨骼、肾脏、肺、皮肤和肝脏中浓度较高。在Vk*MYC多发性骨髓瘤小鼠模型中，PT-112的单药及联合用药均显示出活性。I期临床数据显示，PT-112单药治疗安全且耐受性良好，确定的II期推荐剂量为360 mg/m²，在28天周期的第1、8、15天给药。研究中观察到了确切的缓解及其他活性信号。

结论：这些结果表明PT-112与标准治疗方案之间缺乏交叉耐药性，并支持了Vk*MYC模型系统的转化研究价值。有必要在多发性骨髓瘤中对PT-112开展进一步的临床研究。

### 第二部分 AI 大师评价

本研究旨在评估新型免疫原性细胞死亡(ICD)诱导剂PT-112在复发/难治性多发性骨髓瘤中的安全性与初步疗效。研究创新性地结合了小鼠体内生物分布与药效学模型，以及一项针对经多线治疗患者的I期临床试验。关键发现表明，PT-112因其焦磷酸盐部分而在骨骼中高度富集，临床上展现出良好的安全性、耐受性及抗肿瘤活性信号，并成功确定了II期推荐剂量。该研究证实了PT-112独特的靶向骨骼机制和新颖的作用方式，为已无标准治疗方案的患者提供了极具潜力的治疗新选择，具有重要的临床转化价值。

---

## 37. 三氯蔗糖的摄入通过扰乱肠道菌群削弱癌症免疫治疗效果

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40742298](https://pubmed.ncbi.nlm.nih.gov/40742298)
**期刊：** Cancer discovery
**PMID：** 40742298
**DOI：** 10.1158/2159-8290.CD-25-0247

### 第一部分 原文与翻译

**英文原标题：** Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption.

**英文摘要原文：**
UNLABELLED: Gut microbiota composition is directly associated with response to immunotherapies in cancer. The impact of diet on the gut microbiota and downstream immune responses to cancer remains unclear. In this study, we show that consumption of a common nonnutritive sweetener, sucralose, modifies microbiome composition, restricts T-cell metabolism and function, and limits immunotherapy response in preclinical models of cancer and patients with advanced cancer treated with anti-PD-1-based immune checkpoint inhibitors. Sucralose consumption is associated with a reduction in microbiota-accessible arginine, and amino acid supplementation or fecal microbiome transfer from anti-PD-1 responder mice completely restores T-cell function and immunotherapy response. Overall, sucralose consumption destabilizes the gut microbiota, resulting in compromised T-cell function and ablated immune checkpoint inhibitor response in cancer.

SIGNIFICANCE: This study highlights an unappreciated role of sucralose in reducing immunotherapy efficacy in both mouse models and samples from patients with cancer through shifts in the microbiome and arginine degradation that lead to T-cell exhaustion. T-cell function and immunotherapy responses are restored through amino acid supplementation. See related commentary by Chandra et al., p. 2196.

**中文摘要译文：**
【摘要】 肠道微生物群的组成与癌症免疫治疗的应答直接相关。饮食对肠道微生物群以及下游抗癌免疫应答的影响尚不明确。在本研究中，我们发现摄入一种常见的无营养甜味剂——三氯蔗糖，会改变微生物组的构成，在癌症的临床前模型以及接受基于抗PD-1的免疫检查点抑制剂治疗的晚期癌症患者中，限制T细胞的代谢和功能，并削弱免疫治疗的应答。三氯蔗糖的摄入与微生物可利用的精氨酸减少有关，而补充氨基酸或从抗PD-1应答小鼠进行粪便微生物群移植，可以完全恢复T细胞功能和免疫治疗应答。总体而言，三氯蔗糖的摄入会破坏肠道微生物群的稳定性，导致T细胞功能受损，并消除癌症免疫检查点抑制剂的治疗应答。

【意义】 本研究通过对小鼠模型和癌症患者样本的研究，揭示了三氯蔗糖在降低免疫治疗功效方面一个未被重视的作用，其机制是通过改变微生物组和促进精氨酸降解，从而导致T细胞耗竭。通过补充氨基酸可以恢复T细胞功能和免疫治疗应答。详情参见Chandra等人在第2196页发表的相关评论。

### 第二部分 AI 大师评价

该研究精准地探讨了常见无营养甜味剂三氯蔗糖对癌症免疫治疗效果的潜在影响。研究综合运用了临床前动物模型与晚期癌症患者样本，揭示了三氯蔗糖通过扰乱肠道微生物组、减少微生物可利用的精氨酸，进而损害T细胞功能，最终削弱抗PD-1免疫检查点抑制剂疗效的关键机制。此项发现具有高度的创新性和临床转化价值，首次将特定的饮食成分与免疫治疗失败直接关联，并提出了补充氨基酸作为潜在逆转策略，为优化癌症患者的治疗方案提供了新的视角。

---

## 38. 揭示卵巢癌新兴亚型的基因组与功能图谱

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40736012](https://pubmed.ncbi.nlm.nih.gov/40736012)
**期刊：** Cancer discovery
**PMID：** 40736012
**DOI：** 10.1158/2159-8290.CD-25-0652

### 第一部分 原文与翻译

**英文原标题：** Decoding the Genomic and Functional Landscape of Emerging Subtypes in Ovarian Cancer.

**英文摘要原文：**
UNLABELLED: Ovarian high-grade serous carcinoma (HGSC) is characterized by pervasive genomic instability and high inter- and intra-tumor heterogeneity. Approximately half of HGSC tumors harbor homologous recombination deficiency (HRD), rendering them vulnerable to PARP inhibitors and platinum-based chemotherapy. In contrast, patients lacking HRD (HR-proficient, HRP) generally respond poorly to current therapies. To overcome heterogeneity and identify relevant HGSC subtypes, we characterized the genomic landscape of 640 tumors from 243 patients using whole-genome sequencing. Our chromosomal instability signature-based analysis characterized the structural variation landscape and revealed five HGSC subtypes, validated in an independent dataset. Two HRD subtypes, associated with BRCA1- or BRCA2-driven alterations, demonstrated favorable treatment responses. Strikingly, three HRP subtypes emerged, marked by unique structural alterations and gene expression patterns, tumor microenvironment interactions, and different chemotherapy responses. Notably, organoid experiments showed subtype-specific sensitivity to CHK1 inhibition, suggesting prexasertib as a potential targeted treatment for most currently untreatable HRP patients.

SIGNIFICANCE: These findings demonstrate that HGSC tumors can be divided into functionally and clinically distinct subtypes, offering new insights into the underlying biology of HGSC and providing a foundation to develop tailored therapeutic strategies for HRP tumors, which currently lack effective options.

**中文摘要译文：**
无标签：卵巢高级别浆液性癌（HGSC）的特点是普遍的基因组不稳定以及高度的肿瘤间和肿瘤内异质性。约半数HGSC肿瘤存在同源重组缺陷（HRD），这使其对PARP抑制剂和铂类化疗敏感。相比之下，缺乏HRD（同源重组功能完整，HRP）的患者通常对现有疗法反应不佳。为克服异质性并识别相关的HGSC亚型，我们利用全基因组测序技术，对来自243名患者的640个肿瘤的基因组图谱进行了表征。我们基于染色体不稳定性特征的分析描绘了结构变异图谱，并揭示了五种HGSC亚型，此发现在一个独立的数据库中得到了验证。其中两种HRD亚型与BRCA1或BRCA2驱动的改变相关，表现出良好的治疗反应。引人注目的是，研究发现了三种HRP亚型，它们具有独特的结构改变、基因表达模式、肿瘤微环境相互作用以及不同的化疗反应。值得注意的是，类器官实验显示出亚型特异性的CHK1抑制敏感性，提示prexasertib可能成为对目前大多数无法治疗的HRP患者的潜在靶向治疗药物。

意义：这些发现表明，HGSC肿瘤可被分为功能上和临床上截然不同的亚型，为深入理解HGSC的基础生物学提供了新见解，并为针对目前缺乏有效治疗方案的HRP肿瘤开发量身定制的治疗策略奠定了基础。

### 第二部分 AI 大师评价

本研究通过大规模全基因组测序，旨在对异质性极高的卵巢高级别浆液性癌（HGSC）进行更精细的分子分型。研究团队基于染色体不稳定性特征，创新性地将HGSC划分为五个亚型，尤其揭示了三种对现有疗法反应不佳的同源重组功能完整（HRP）亚型独特的基因组和功能特征。其核心价值在于，不仅深化了对HGSC生物学复杂性的理解，更重要的是通过类器官实验发现了针对HRP亚型的潜在靶向药物（CHK1抑制剂），为这部分缺乏有效治疗方案的患者带来了新的希望，为实现卵巢癌的精准治疗和个体化策略制定提供了坚实的科学依据。

---

## 39. 核孔外核孔蛋白sPOM121在转录层面驱动β-catenin介导的前列腺癌肿瘤进展和免疫逃逸

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40709833](https://pubmed.ncbi.nlm.nih.gov/40709833)
**期刊：** Cancer discovery
**PMID：** 40709833
**DOI：** 10.1158/2159-8290.CD-25-0629

### 第一部分 原文与翻译

**英文原标题：** Off-pore Nucleoporin sPOM121 Transcriptionally Propels β-Catenin-driven Tumor Progression and Immune Escape in Prostate Cancer.

**英文摘要原文：**
UNLABELLED: The roles of nucleoplasm-residing nucleoporins (NUP) in solid tumors, including prostate cancer, remain unknown. In this study, we reveal the clinical significance and mechanistic role of the off-pore NUP, soluble POM121 (sPOM121), as a crucial transcriptional regulator that enhances the aggressiveness of metastatic prostate cancer. Using orthogonal methodologies in human samples, sPOM121 was identified as the predominantly expressed nucleoplasmic NUP in prostate cancer. Unbiased proteomic and epigenomic studies demonstrate that sPOM121, through its C-terminus, interacts with the chromatin remodeler SMARCA5 at gene promoter sites and localizes at nuclear condensates, reprogramming gene expression. Indeed, sPOM121 regulates a distinct oncogenic gene network, including β-catenin, leading to prostate cancer progression and immune evasion. Importantly, targeting the sPOM121/β-catenin axis in patient-derived preclinical and syngeneic mouse models halts prostate cancer aggressiveness and enhances antitumor immunity. Taken together, these findings reveal previously unknown actionable reprogramming functions of off-pore NUPs in solid tumors.

SIGNIFICANCE: This study uncovers how oncogenic signaling programs are transcriptionally heightened by the NUP sPOM121 in metastatic prostate cancer. Localization of sPOM121 at active transcriptional nuclear condensates propels disease progression and immune evasion, offering novel anticancer therapeutic opportunities.

**中文摘要译文：**
核质内核孔蛋白（NUP）在包括前列腺癌在内的实体瘤中的作用尚不明确。在本研究中，我们揭示了核孔外核孔蛋白——可溶性POM121（sPOM121）作为一种关键转录调节因子，在增强转移性前列腺癌侵袭性方面的临床意义和机制性作用。通过对人类样本采用正交方法学研究，sPOM121被鉴定为前列腺癌中主要表达的核质内核孔蛋白。无偏倚的蛋白质组学和表观基因组学研究表明，sPOM121通过其C-末端与染色质重塑因子SMARCA5在基因启动子位点相互作用，并定位于核凝聚体，从而重编程基因表达。确实，sPOM121调控着一个包括β-catenin在内的独特致癌基因网络，进而导致前列腺癌进展和免疫逃逸。重要的是，在源自患者的临床前模型和同系小鼠模型中，靶向sPOM121/β-catenin轴能够抑制前列腺癌的侵袭性并增强抗肿瘤免疫。综上所述，这些研究结果揭示了核孔外核孔蛋白在实体瘤中一种前所未知的、可作为治疗靶点的重编程功能。

研究意义：本研究揭示了在转移性前列腺癌中，致癌信号通路是如何被核孔蛋白sPOM121在转录水平上增强的。sPOM121在活性转录核凝聚体中的定位驱动了疾病进展和免疫逃逸，为开发新的抗癌疗法提供了机会。

### 第二部分 AI 大师评价

该研究聚焦于核孔外核孔蛋白sPOM121在转移性前列腺癌中的非经典功能。研究综合运用蛋白质组学、表观基因组学及临床前动物模型，关键性地发现sPOM121能作为转录调节因子，通过激活β-catenin信号通路来驱动肿瘤进展和免疫逃逸。这项工作的显著创新性在于揭示了核孔蛋白在肿瘤转录重编程中的直接作用，为治疗侵袭性前列腺癌提出了一个极具潜力的新靶点，具有重要的临床转化价值。

---

## 40. 染色体外MYC旁系同源基因扩增塑造小细胞肺癌的免疫抑制性肿瘤微环境

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40299768](https://pubmed.ncbi.nlm.nih.gov/40299768)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 40299768
**DOI：** 10.1158/1078-0432.CCR-24-3399

### 第一部分 原文与翻译

**英文原标题：** Amplification of Extrachromosomal MYC Paralogs Shapes Immunosuppressive Tumor Microenvironment in Small Cell Lung Cancer.

**英文摘要原文：**
PURPOSE: Immunotherapy has demonstrated promise in small cell lung cancer (SCLC), but certain patients encounter limited benefits, highlighting the need for immunosuppressive biomarkers. Extrachromosomal circular DNA (ecDNA) promotes amplification of MYC paralogs (MYC, MYCN, and MYCL), driving cross-resistance in SCLC. In this study, we aim to investigate whether ecDNA-mediated MYC paralog amplification (ecMYC+) represents immunosuppressive features in SCLC.

EXPERIMENTAL DESIGN: Bulk RNA sequencing data were retrieved from public database and paraffin-embedded samples. The overexpression and amplification of MYC paralogs were identified using IHC and FISH. Imaging mass cytometry and multiplex IHC were used to characterize spatial distribution of the tumor immune microenvironment. The copy number of MYC paralogs was investigated using qRT-PCR. RNA sequencing and flow cytometry were performed in SCLC cell lines.

RESULTS: The mean copy number of ecDNAs and the frequency of ecMYC+ cell lines were higher in SCLC than those in the other lineages (SCLC 22/47 vs. others 15/282). In ecMYC+ SCLC, multiple immune-related pathways were downregulated whereas nucleotide metabolism processes were upregulated. Inhibition of nucleotide metabolism induced ecDNA elimination, along with activated antigen presenting pathways. Highly dispersed MYC paralog amplifications were detected in resected treatment-naïve SCLC samples. Through the resolution of 103,341 cells from 24 pathologic regions, we observed higher expression of Ki67, VEGFA, FAP, and FOXP3 and reduced T-cell infiltration in ecMYC+ samples. Moreover, ecMYC+ samples exhibited elevated cellular neighborhoods dominated by Ki67+ tumors, with reduced spatial interaction with immune cells.

CONCLUSIONS: Extrachromosomal amplification of MYC paralogs shapes the suppressive tumor immune microenvironment, identifying potential subgroups of immunotherapy-resistant patients.

**中文摘要译文：**
目的：免疫疗法在小细胞肺癌（SCLC）中已显示出前景，但部分患者获益有限，这凸显了寻找免疫抑制性生物标志物的必要性。染色体外环状DNA（ecDNA）能促进MYC旁系同源基因（MYC、MYCN和MYCL）的扩增，从而驱动SCLC的交叉耐药。本研究旨在探讨ecDNA介导的MYC旁系同源基因扩增（ecMYC+）是否在SCLC中表现出免疫抑制特征。

实验设计：从公共数据库和石蜡包埋样本中获取批量RNA测序数据。使用免疫组织化学（IHC）和荧光原位杂交（FISH）技术鉴定MYC旁系同源基因的过表达与扩增。采用成像质谱流式细胞术和多重免疫组织化学技术来表征肿瘤免疫微环境的空间分布。通过qRT-PCR研究MYC旁系同源基因的拷贝数。在SCLC细胞系中进行了RNA测序和流式细胞术分析。

结果：SCLC中ecDNA的平均拷贝数和ecMYC+细胞系的频率均高于其他细胞谱系（SCLC为22/47，其他为15/282）。在ecMYC+的SCLC中，多条免疫相关通路被下调，而核苷酸代谢过程则被上调。抑制核苷酸代谢可诱导ecDNA消除，并激活抗原呈递通路。在切除的初治SCLC样本中检测到高度分散的MYC旁系同源基因扩增。通过对来自24个病理区域的103,341个细胞进行解析，我们观察到在ecMYC+样本中，Ki67、VEGFA、FAP和FOXP3的表达更高，而T细胞浸润减少。此外，ecMYC+样本表现出由Ki67+肿瘤细胞主导的细胞邻域增多，且与免疫细胞的空间相互作用减少。

结论：染色体外MYC旁系同源基因的扩增塑造了抑制性的肿瘤免疫微环境，这有助于识别可能对免疫疗法产生耐药的患者亚群。

### 第二部分 AI 大师评价

本研究聚焦于小细胞肺癌（SCLC）的免疫治疗耐药机制，创新性地将染色体外DNA（ecDNA）介导的MYC旁系同源基因扩增与免疫抑制性肿瘤微环境的形成联系起来。研究综合运用了多组学分析、先进的成像技术和分子生物学方法，揭示了ecMYC+肿瘤中存在免疫通路下调、T细胞浸润减少以及免疫细胞空间互作减弱等“冷”肿瘤特征。这项发现不仅为筛选免疫治疗不敏感的SCLC患者提供了潜在的新型生物标志物，还提示靶向核苷酸代谢可能成为逆转免疫抑制、增敏免疫治疗的新策略，具有重要的临床转化价值。

---

## 41. Izalontamab (SI-B001)，一种新型EGFRxHER3双特异性抗体，在局部晚期或转移性上皮性肿瘤患者中的首次人体I/Ib期研究结果

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40260627](https://pubmed.ncbi.nlm.nih.gov/40260627)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 40260627
**DOI：** 10.1158/1078-0432.CCR-25-0206

### 第一部分 原文与翻译

**英文原标题：** Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study.

**英文摘要原文：**
PURPOSE: Izalontamab (SI-B001) is a novel EGFR×HER3 bispecific antibody. This first-in-human phase I study presents the safety and pharmacokinetics of izalontamab.

PATIENTS AND METHODS: Previously treated patients with locally advanced or metastatic epithelial tumors were enrolled in the dose-escalation or dose-expansion phases. The dose-escalation phase consisted of an accelerated titration and a "3 + 3" design with nine dose levels from 0.4 to 28.0 mg/kg. The dose-expansion phase included five dose levels from 6.0 to 21.0 mg/kg. Izalontamab was administered intravenously weekly or every 2 weeks in a 4-week cycle. Available pretreatment specimens were obtained to explore the relationship between EGFR/HER3 expression and efficacy.

RESULTS: Sixty patients were enrolled. Among the 60 enrolled patients, 49 had non-small cell lung cancer (NSCLC), 6 had nasopharyngeal cancer, 3 had head and neck cancer squamous cell carcinoma, and 2 had other types of cancer. The most common treatment-related adverse events were rash (42%), paronychia (25%), and infusion-related reactions (23%). No drug-related death occurred. Izalontamab displayed a nonlinear pharmacokinetic behavior, and clearance at steady state seemed to be approaching a dose-independent value at 6 mg/kg and above. The best response included two confirmed partial responses in patients with NSCLC and head and neck cancer squamous cell carcinoma; 18 patients had stable disease, including NSCLC (n = 17) and colorectal cancer (n = 1). The recommended phase II dose for izalontamab was determined as 9 to 16 mg/kg weekly.

CONCLUSIONS: Izalontamab was well tolerated and demonstrated preliminary antitumor activity in patients with locally advanced or metastatic epithelial tumors, supporting it as a promising therapeutic candidate for combination therapies, with a phase III study currently underway.

**中文摘要译文：**
目的：Izalontamab (SI-B001) 是一种新型的EGFR×HER3双特异性抗体。本项首次人体I期研究旨在报告izalontamab的安全性与药代动力学特性。

患者与方法：既往接受过治疗的局部晚期或转移性上皮性肿瘤患者被纳入剂量递增或剂量扩展阶段。剂量递增阶段采用加速滴定和“3+3”设计，包含从0.4至28.0 mg/kg的九个剂量水平。剂量扩展阶段则包括从6.0至21.0 mg/kg的五个剂量水平。Izalontamab以4周为一个周期，每周或每两周静脉注射一次。研究获取了可用的治疗前标本，以探究EGFR/HER3表达与疗效之间的关系。

结果：共纳入六十名患者。在60名入组患者中，49例为非小细胞肺癌（NSCLC），6例为鼻咽癌，3例为头颈部鳞状细胞癌，2例为其他类型癌症。最常见的治疗相关不良事件为皮疹（42%）、甲沟炎（25%）和输液相关反应（23%）。未发生与药物相关的死亡事件。Izalontamab表现出非线性的药代动力学行为，在6 mg/kg及以上剂量时，稳态清除率似乎接近一个剂量非依赖性的数值。最佳缓解包括在非小细胞肺癌和头颈部鳞状细胞癌患者中观察到的两例经确认的部分缓解；18名患者病情稳定，包括非小细胞肺癌（n=17）和结直肠癌（n=1）。最终确定的izalontamab II期推荐剂量为每周9至16 mg/kg。

结论：Izalontamab在局部晚期或转移性上皮性肿瘤患者中表现出良好的耐受性，并显示出初步的抗肿瘤活性，这支持其作为一种有前景的联合治疗候选药物，目前一项III期研究正在进行中。

### 第二部分 AI 大师评价

本研究是一项关于新型EGFRxHER3双特异性抗体Izalontamab的首次人体I/Ib期临床试验，旨在评估该药物在晚期上皮性肿瘤患者中的安全性、药代动力学特征，并初步探索其抗肿瘤活性。研究结果表明，Izalontamab具有良好的耐受性，并展现了初步的抗肿瘤效果，成功确定了II期临床试验的推荐剂量。这项研究的价值在于为靶向EGFR和HER3双靶点的抗肿瘤新药开发提供了关键的早期临床证据，为后续在非小细胞肺癌等实体瘤中的进一步研究奠定了基础，具有重要的临床转化潜力。

---

速递结束，祝您工作愉快！